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Abbreviations 
 
AC Acid ceramidase (human AC, murine Ac) 
ACPA Anti-citrullinated protein antibody 
AIA Antigen induced arthritis 
ASAH1 N-acylsphingosine amidohydrolase 1 (human gene ASAH1, murine Asah1) 
ASM Acid sphingomyelinase (human ASM, murine Asm) 
bSM Bacterial sphingomyelinase 
CF Cystic fibrosis 
CFA Complete Freud’s adjuvant 
CXCL Chemokine C-X-C motif ligand  
DMARD Disease modifying anti rheumatic drug 
ELISA Enzyme-linked immunosorbent assay 
FCS Fetal calf serum 
FD Farber disease 
FDA Food and drug administration agency 
FIASMA Functional inhibitor of acid sphingomyelinase 
GALT Gut-associated lymphoid tissue 
GC Glucocorticoid 
GPT Glutamic-pyruvic transaminase (also known as alanine transaminase) 
GOT Glutamic oxaloacetic transaminase (also known as aspartate transaminase) 
HLA Human leukocyte antigen  
i.m. Intramuscular  
i.p. Intraperitoneally 
i.v. Intravenously 
IL Interleukin 
iNOS Inducible NO synthase 
LAMP-1 Lysosomal-associated membrane protein 1 
L-ASM Lysosomal acid sphingomyelinase 
LDH Lactate dehydrogenase 
MAPK Mitogen-activated protein kinase 
mBSA Methylated bovine serum albumin 
MCP-1 Monocyte chemoattractant protein 1 
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MMP Matrix metalloproteinase 
MTX Methotrexate 
NK Natural killer cells 
NO Nitric oxide 
PBMC Peripheral blood mononuclear cell 
PBS Phosphate-buffered saline 
PFA Paraformaldehyde 
PHA Phytohaemagglutinin 
RA Rheumatoid arthritis 
RF Rheumatoid factor 
rhAC Recombinant human acid ceramidase 
RNS Reactive nitrogen species 
ROS Reactive oxygen species 
S-ASM Secretory acid sphingoymelinase 
SMPD1 Sphingomyelin phosphodiesterase 1 (human gene SMPD1, murine Smpd1) 
SGLT Sodium-glucose linked transporters  
SSZ Sulfasalazine 
TGFß Transforming growth factor ß 
TLC Thin layer chromatography 
TNF-α  Tumor necrosis factor α 
VEGF Vascular endothelial growth factor 
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1. Abstract 
 
Acid sphingomyelinase is a lysosomal enzyme that catalyzes the hydrolysis of sphingomyelin 
to ceramide. Acid sphingomyelinase/ceramide have been implicated in the pathogenesis of a 
number of different diseases. Pharmacological inhibitors of acid sphingomyelinase are already 
in clinical use and are well tolerated. Thus, this study aimed to expand the existing applications 
of known acid sphingomyelinase inhibitors to acid sphingomyelinase/ceramide-related diseases 
with a currently unmet clinical treatment need.  
Farber disease is a rare lysosomal storage disorder caused by ceramide accumulation due to 
acid ceramidase deficiency. This study introduces a new mouse model to study FD that mirrors 
the human disease closely. Cross-breeding of these mice to acid sphingomyelinase-deficient 
mice reduced ceramide accumulation, improved disease manifestations and prolonged survival. 
Pharmacological inhibition of acid sphingomyelinase, however, failed due to unexpected, 
genotype-specific toxicity.  
In rheumatoid arthritis, an autoimmune disorder affecting predominantly the joints, ceramide 
levels in the synovial fluid of patients have been reported to be elevated. Using a mouse model 
of inflammatory arthritis, this study analyzed the role of acid sphingomyelinase in joint 
inflammation and shows that both genetic ablation and pharmacological inhibition of acid 
sphingomyelinase ameliorates arthritis severity.  
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Zusammenfassung 
Das Enzym Saure Sphingomyelinase katalysiert die Hydrolyse von Sphingomyelin zu Ceramid. 
Saure Sphingomyelinase und Ceramid spielen eine Rolle in der Pathogenese einer Reihe 
verschiedener Erkrankungen. Pharmakologische Inhibitoren der Sauren Sphingomyelinase 
werden bereits in der Klinik eingesetzt und sind gut verträglich. Das Ziel dieser Arbeit war es 
deshalb, die Anwendungsgebiete dieser bereits eingesetzten Inhibitoren auf Erkrankungen zu 
erweitern, bei denen die Saure Sphingomyelinase und/oder Ceramid eine Rolle spielen und die 
bislang nur unzureichend behandelt werden können.  
Farber Lipogranulomatose ist eine seltene lysosomale Speichererkrankung, bei der es aufgrund 
einer Sauren Ceramidase-Defizienz zu einer Anreicherung von Ceramid kommt. Diese Arbeit 
stellt ein neues Mausmodell zur Erforschung der Erkrankung vor, dass den Phänotyp der 
humanen Erkrankung wiederspiegelt. Die Kreuzung dieser Mäuse mit Saure 
Sphingomyelinase-defizienten Mäusen reduzierte die Ceramid-Akkumulation, verbesserte die 
Symptome und verlängerte das Überleben der Farber-Mäuse. Die pharmakologische Inhibition 
scheiterte jedoch aufgrund unerwarteter, Genotyp-spezifischer Toxizität.  
Rheumatoide Arthritis ist eine Autoimmunerkrankung, die vor allem die Gelenke betrifft. In 
der Synovialflüssigkeit von Patienten mit dieser Erkrankung wurden erhöhte Ceramid-Spiegel 
festgestellt. Mithilfe eines Mausmodells für entzündliche Arthritis wurde in dieser Arbeit die 
Rolle der Sauren Sphingomyelinase bei Gelenkentzündungen untersucht. Sowohl durch 
genetische Deletion als auch durch pharmakologische Inhibition der sauren Sphingomyelinase 
konnte die Gelenkentzündung reduziert werden.  
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2. Introduction 
2.1 Acid sphingomyelinase 
2.1.1 Structure and maturation 
Acid sphingomyelinase (human ASM, murine Asm; Enzyme Commission Classification number 
3.1.4.12) catalyzes the hydrolysis of sphingomyelin to phosphorylcholine and  
ceramide with an acidic pH optimum. It is encoded by one conserved gene (human SMPD1, 
 murine Smpd1) of 5-6 kb located on the p15.1-p15.4 region of chromosome 11. The gene 
encompasses 6 exons and yields 7 isoforms, of which only the one containing all six exons is 
catalytically active (Rhein et al. 2012; Schuchman et al. 1991).  
The nascent polypeptide (pre-pro-ASM) contains a signal peptide, saposin-domain, proline- 
rich linker, catalytic metallophosphatase (phosphodiesterase) domain and a carboxy-terminal  
region (Fig. 1). The signal peptide targets pre-pro-ASM to the endoplasmatic reticulum,  
where it is then cleaved. The resulting pro-ASM is glycosylated, which determines further  
cellular trafficking and later activity: High-mannose oligosaccharides yield lysosomal ASM  
(L-ASM); complex N-glycosylation yields secretory ASM (S-ASM) (Hurwitz et al. 1994; Schissel, 
Keesler, et al. 1998). Since S-ASM is secreted via the Golgi secretory pathway, this precursor 
depends on extracellular Zn2+ ions for activation, whereas L-ASM binds  
intracellular Zn2+ ions during trafficking to lysosomes (Schissel, Keesler, et al. 1998). The  
typical C-terminal cleavage of lysosomal hydrolases within the endolysosomal compartment  
is thought to promote the coordination of lysosomal Zn2+ ions by L-ASM: The C-terminal  
Cys6311 residue of L-ASM is involved in the coordination of the active site Zn2+ ion, keeping  
the enzyme in the low activity form. C-terminal cleavage eliminates Cys631, thus enhancing 
activity (Qiu et al. 2003). Cleavage occurs at either a canonical-site or at a non-canonical site  
by Caspase-7 (Edelmann et al. 2011). S-ASM, on the other hand, still contains Cys631,  
enabling regulation by oxidation-driven dimerization for full activation (Qiu et al. 2003). 
Essentially, this cysteine-dependent regulatory mechanism is identical to the “cysteine  
switch” described for metalloproteinases. The recently identified crystallographic structure of  
ASM adds further support to this: The saposin-domain of ASM can interact with the C- 
terminal domain, thus adopting a closed conformation that keeps the enzyme inactive. In the  
active enzyme, the saposin-domain establishes an interface with the catalytic domain. The  
catalytic domain itself forms a calcineurin-like fold with two zinc ions, with the linker  
wrapping around the catalytic domain (Gorelik et al. 2016; Xiong et al. 2016).  
                                                          
1 All amino acids are numbered according to the reference sequence NM_000543.4 throughout this work. 
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Figure 1: Protein domain structure of acid sphingomyelinase - Schematic representation of ASM-protein 
domains, including important posttranslational modifications. (Beckmann et al. 2017).  
 
2.1.2. Signaling through ceramide-enriched platforms 
Activation of ASM results in a reorganization of the plasma membrane. The “fluid mosaic 
model” by Singer and Nicolson was the first model to describe the organization of biological 
membranes, postulating a random distribution of lipids and free movement of proteins within 
the membrane (Singer and Nicolson 1972). This “fluid-disordered” model has since been 
overturned by a liquid-ordered model: Hydrophilic and hydrophobic interactions of lipids with 
each other promote the formation of ordered structures termed “lipid rafts” (Brown and London 
1998; Simons and Ikonen 1997). 
Biological membranes contain three main classes of lipids – glycerolipids, sterols and 
sphingolipids. Sphingolipids contain one of five sphingoid bases (unsaturated amino-alcohol) 
as a backbone, linked to one fatty acid through an amide bond. Variability is achieved both in 
the hydrophobic part – by different chain-length, saturation-status and degree of fatty-acid-
hydroxylation – and the hydrophilic part, by addition of hydroxyl-groups, phosphates and/or 
sugar residues. Interactions between sphingolipids also occur in both parts: The hydrophobic 
tails of sphingolipids interact with each other and with cholesterol via van-der-Waal 
interactions, whereas the polar head-groups interact via hydrophilic forces.  
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These interactions can result in distinct membrane domains. Particularly, ceramide molecules, 
product of ASM-mediated sphingomyelin hydrolysis, self-associate by the abovementioned 
forces. Thereby, they separate themselves and other lipids within the membrane, resulting in 
the formation of small, ceramide-enriched domains. These, in turn, spontaneously fuse to even 
larger membrane domains, which are then termed platforms. Platform-formation reorganizes 
receptors and signaling molecules within the membrane, as proteins also associate with 
ceramide moieties (or are repelled) by the same biophysical and energetic forces. Protein 
reorganization does not only depend on the composition of a given protein’s transmembrane 
domain, but also on its structure – e.g. ligand binding may induce a conformational change that 
alters the transmembrane domain in such a way that the ceramide-interacting moieties are 
exposed, enabling the sorting into ceramide-enriched platforms only after ligand binding. 
Additionally, attraction to- or repulsion from platforms can also be mediated by the lipid 
cofactors of a given protein.  
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Figure 2: Ceramide-enriched platform formation – Upon activation and translocation of ASM to the plasma 
membrane, ceramide is generated from the abundant membrane lipid sphingomyelin. The resulting alteration 
to the biophysical properties of the membrane lead to the formation of small, ceramide-enriched microdomains. 
These fuse to form ceramide-enriched membrane platforms, which redistribute receptors and signaling 
molecules within the membrane, facilitating signal transmission. (Beckmann et al. 2017).  
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The reorganization of receptors and signaling molecules in ceramide-enriched platforms can 
act in several ways: By resulting in clustering of receptors, a high receptor density, spatial 
focusing of activated receptors with intracellular molecules, exclusion of inhibitory molecules 
and/or the transactivation of other enzymes. All this facilitates the transmission of a given signal 
across the membrane into the cell. Additionally, it enables generation of a strong, localized 
signal. Signaling via ceramide-enriched platforms is a unique mechanism and distinct from the 
stoichiometrical action of classical second messenger signaling. It also explains why various 
stimuli that activate ASM and induce platform formation can have so many different cellular 
effects.  
ASM seems to typically signal via the formation of ceramide-enriched plasma-membrane 
platforms, while a signaling function of the intralysosomal protein is presently unknown. Given 
that these domains are formed in the plasma membrane, whereas ASM is present in the 
endolysosomal compartment (L-ASM) or secretory vesicles (S-ASM), ASM translocation is 
required in conjunction with ASM activation. L-ASM containing secretory lysosomes fuse with 
the plasma membrane in a syntaxin-4-dependent process (Perrotta et al. 2010), depositing L-
ASM to the extracellular leaflet of the plasma membrane. Since the secretory lysosomes also 
include proton pumps, an acidic milieu is maintained locally in the subsequently formed 
ceramide-platforms, allowing optimal activity of ASM (Xu et al. 2012). It is important to note, 
however, that the lipid composition of the membrane alters the Michaelis-Menten constant (Km) 
of ASM, thus also permitting ASM activity at higher pH (Schissel, Jiang, et al. 1998; Schissel, 
Keesler, et al. 1998). Since the generation of ceramide-enriched membrane platforms is a 
general mechanism reorganizing a given signalosome, not a specific signaling event, these 
platforms are able to play a role in the signaling of many receptors and cell stimuli. Thus, a 
large number of stimuli are known to trigger the formation of these membrane domains (an 
extensive list is provided in Table 1).  
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Table 1: ASM-activating stimuli – Overview of stimuli inducing ASM activation and/or ceramide-enriched 
platform formation (Beckmann et al. 2014).  
 
 
2.1.3 Physiological Inhibition of ASM-mediated Signaling 
Several innate ASM-inhibitory mechanisms have been described: Some of the alternative splice 
variants of ASM lack the catalytic and/or carboxy-terminal domains (transcripts 5, 6 and 7) and 
function as dominant-negative proteins (Rhein et al. 2012). Additionally, inositol-phosphates 
inhibit ASM. However, the physiological significance of their inhibitory interaction with ASM 
is not yet known (Kolzer et al. 2003).  
The translocation of L-ASM can be inhibited by nitric oxide (NO), which induces 
phosphorylation of syntaxin-4 via activation of G-kinase, thus preventing the fusion of 
secretory lysosomes with the plasma membrane (Perrotta et al. 2010).  
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Pharmacologically, a number of functional inhibitors of ASM (FIASMAs) have been identified. 
These will be discussed in more detail in the next section (2.2 – Pharmacological inhibitors of 
ASM).  
 
2.1.4 ASM in disease 
ASM was originally identified as the cause of the lysosomal storage disorder Niemann-Pick 
disease type A and B (Brady et al. 1966). Patients exhibit varying degrees of lipid storage and 
foam cell infiltration in tissues and clinically present with hepatosplenomegaly (type A and B), 
CNS involvement (type A) and lung involvement (type B). Type A patients typically die in 
early childhood, whereas disease progression is more variable in type B patients, who often 
survive into adulthood (reviewed in (Schuchman and Desnick 2017)).  
In addition to Niemann-Pick disease, the ASM/ceramide system has been reported to play a 
role in the pathophysiology of a number of different diseases, including cardiovascular-, 
metabolic-, hepatic-, inflammatory and infectious diseases, as well as in cancer and tumor 
metastasis (please see Table 2 for more specific examples).  
Table 2: Acid sphingomyelinase-related diseases – Overview of diseases, which have been linked to 
ASM/ceramide signaling. To be published in Beckmann et al. 2017.  
 
Introduction 
 
18 
 
Currently, the role of ASM in major depression is the only one clinically exploited, as a number 
of long-standing antidepressant drugs are actually ASM inhibitors: Originally, these tricyclic 
antidepressants were thought to inhibit monoamine uptake, but the identification of their ASM 
inhibitory capacity (Hurwitz, Ferlinz, and Sandhoff 1994) has led to an investigation into the 
role of ASM in major depression (Grassmé et al. 2015; Gulbins et al. 2016; Gulbins et al. 2013). 
These studies have since revealed that these drugs exert their antidepressant effect by inhibiting 
ASM and thus reducing hippocampal ceramide concentrations as well as increasing neuronal 
proliferation, maturation and survival (Grassmé et al. 2015; Gulbins et al. 2016; Gulbins et al. 
2013). 
ASM inhibitors are also being tested in clinical studies to treat cystic fibrosis (CF): Ceramide 
has been shown to mediate inflammation, cell death and infection susceptibility in CF 
(Teichgräber et al. 2008). Targeting ceramide accumulation with the ASM inhibitor 
Amitriptyline has had favorable results in a recently reported phase II clinical study (Adams et 
al. 2016) and is currently under investigation in a phase III clinical trial.   
 
2.2 Pharmacological inhibitors of ASM 
2.2.1 Functional inhibitors of ASM 
Antidepressant drugs like Amitriptyline functionally inhibit ASM. FIASMAs are weak bases 
and thus accumulate in the lysosomes due to acid trapping: In their neutral state, they can 
passively diffuse across membranes. In acidic compartments like the lysosome, however, they 
become protonated and thus lose their ability to cross the membrane (Daniel and Wojcikowski 
1997; Ishizaki et al. 1996; Kornhuber, Retz, and Riederer 1995; Trapp et al. 2008). It is 
proposed that due to their high lipophilicity, they then interfere with ASM-membrane 
attachment. L-ASM attaches to the inner membrane leaflet of the lysosome by electrostatic 
forces. Without membrane attachment, there is no contact to its substrate sphingomyelin. 
Further, unbound L-ASM is a target for lysosomal proteases. Thus, FIASMAs result in 
abrogation of ASM activity and induce subsequent proteolytic degradation of L-ASM (Kolzer, 
Werth, and Sandhoff 2004). Weak basicity and high lipophilicity are the physicochemical 
properties required for ASM inhibition by these drugs – rather than a specific structural motive 
(Kornhuber et al. 2010; Kornhuber et al. 2008). The recent identification of the structure of 
ASM has not conflicted this model. It does, however, also allow for the possibility that these 
drugs bind to the hydrophobic surface of the saposin domain and thus prevent saposin-substrate 
interaction (Zhou et al. 2016).  
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Figure 3: Mechanism of action of functional acid sphingomyelinase inhibitors – Due to acid trapping, 
FIASMAs accumulate in the lysosomes. Their lipophilic moieties anchor them in the membrane, exposing their 
protonated portion to the lumen. This alters the electrostatic dynamics of the inner lysosomal membrane and 
disrupts the electrostatic adherence of ASM, thereby inactivating the enzyme and targeting it for proteolytic 
degradation (Beckmann et al. 2014)  
Extensive screening has identified a large number of substances as FIASMAs (Kornhuber et al. 
2011; Kornhuber et al. 2008), most of them already in clinical use, e.g. the tricyclic 
antidepressants Amitriptyline, Desipramine, Imipramine and Fluoxetine. Favorable properties 
of FIASMAs include good absorption (all are orally active), distribution (extensive tissue 
binding, most can also cross the blood-brain barrier), metabolism and excretion, activity across 
different cell types, no habituation, reversible inhibition and no rebound effects (Kornhuber et 
al. 2010). Additionally, the inhibitory effects of FIASMAs are limited to the lysosomes, so 
neutral and alkaline sphingomyelinases are not affected. Concerning specificity, there also is 
no gross general inhibitory effect on other lysosomal hydrolases (Kornhuber et al. 2010). A few 
lysosomal enzymes, however, have been reported to be co-inhibited by cationic amphiphilic 
drugs, namely acid ceramidase (human AC, mouse Ac), lysosomal acid lipase and 
phospholipase A and C (Kornhuber et al. 2010). AC, for example, has been reported to be 
inhibited by Desipramine in vitro (Elojeimy et al. 2006).  
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2.2.2 Other inhibitors of ASM 
Another option to inhibit ASM is by using sphingomyelin analogues which cannot be cleaved 
by ASM. Two such analogues ((3R,4S)-1,1-dufloro-4-hydroxy-3-palmitoylamino)-4-
phenoylbutylphosphonic acid and AD2765) have been described, but both are clinically 
unsuitable because they are not selective: One also inhibited other sphingomyelinases 
(Yokomatsu et al. 2003) and the other (AD2764) also inhibited sphingomyelin synthase, thus 
even increasing ceramide concentrations (Darroch et al. 2005).  
Some natural products isolated from the bark of Garcinia speciosa (α-mangostin, cowanin, 
cowanol) were also reported to inhibit ASM, however, they had greater selectivity for neutral 
sphingomyelinase (Okudaira et al. 2000) and subsequently synthesized substances (α-
mangostin derivates) were less active overall (Hamada et al. 2003).  
Phosphoinositides, such as phosphatidyl-myo-inositol-3,4,5-trisphosphate (Testai et al. 2004) 
and phosphatidyl-D-myoinositol-3,5-bisphosphate (Kolzer et al. 2003), are potent and selective 
physiological inhibitors of ASM. Unfortunately, they are ill suited for clinical application, as 
they are biologically active themselves, substrates for a variety of enzymes and unable to 
penetrate membranes and distribute intracellularly (Arenz 2010). The later feature, however, 
enables topical ASM inhibition in contexts where systemic ASM suppression is unneeded or 
unwanted. For instance, local administration of phosphatidyl-D-myoinositol-3,5-bisphosphate 
has been successfully used to improve oxygenation and pulmonary edema in an acute lung 
injury model (Preuss et al. 2012). 
Several bisphophosphonates can also directly inhibit ASM (Roth et al. 2009). Zolendronic acid, 
for instance, is currently used for the treatment of osteoporosis. At present, however, it is 
unclear whether or not the bisphosphonates in current clinical use actually inhibit ASM in vivo 
and at therapeutic concentrations.  
 
2.3. Acid ceramidase and Farber disease 
2.3.1 Background, structure and maturation of acid ceramidase 
Acid ceramidase (human AC, murine Ac; Enzyme Commission Classification number  
3.5.1.23; also known as N-acylsphingosine deacylase) is the lipid hydrolase that acts 
downstream of ASM by deacetylating ceramide to sphingosine and free fatty acid.  
Importantly, however, AC can also catalyze the reverse reaction at a higher pH (Okino et al. 
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 2003). Similar to ASM, AC also exists in a lysosomal and a secreted form (Ferlinz et al.  
2001).  
The AC gene (human ASAH1, murine Asah1) is located on the short arm of chromosome 8 
(p21.3-22) and encompasses 14 exons and 13 introns (Li et al. 1999). The AC protein is 
synthesized as a precursor, which is glycosylated by Peptido-N-glycase and Endo-H and 
proteolytically processed into an α- and ß-subunit (Ferlinz et al. 2001). The later contains the 
catalytic domain. C-terminal processing also occurs (He et al. 2003). The processing enzymes 
and the precise subcellular localization of the precursors are presently unknown. The mature 
enzyme has been shown to form a multi-enzyme complex with ASM and a ß-galactosidase 
(putatively the one that uses galactosylceramide as a substrate) and requires Saposin D for 
activity (Azuma et al. 1994; He et al. 2003; Klein et al. 1994).   
Deficiency of AC was identified as the cause of Farber Disease (FD) and has been linked to 
several cancers and Alzheimer’s disease (reviewed in (Park and Schuchman 2006)). 
 
 
Figure 4: Structure of the ASAH1 gene and the acid ceramidase protein – Illustration of the structure of 
the gene encoding AC (a), its cDNA structure (b) and protein domains (c). Sites of (putative) posttranslational 
modifications are indicated, as well as reported mutations. (Moser 2001). 
 
2.3.2 Farber Disease 
FD is a lysosomal storage disorder resulting from deficiency in AC, leading to an accumulation 
of lysosomal ceramide. The disease typically involves a triad of deformed  
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joints, subcutaneous nodules and progressive hoarseness. Histology shows granulomas and 
lipid-laden macrophages, which is why the disease is also known as Farber lipogranulomatosis. 
Since the first description by Sidney Farber in 1957 (Farber, Cohen, and Uzman 1957), 7 
subtypes have been classified (Moser 2001). Subtype-I and IV patients have the most severe 
phenotype and most only survive for up to two years. Neurological involvement (type I) and/or 
hepatosplenomegaly (type IV) are common, as well as lung and heart involvement. The lungs 
have been reported to be involved in all severely affected patients and pulmonary disease is the 
most common cause of death in these patients. Some patients with a less severe phenotype 
survive into adulthood. The variability in disease severity and affected tissues cannot be 
explained so far – residual enzyme activity in in vitro assays does not appear to correlate with 
disease phenotype (Moser 2001).  
FD is a very rare autosomal-recessive disease with a high frequency of consanguinity in the 
approximately 100 reported cases. Hence, the pathophysiology is only poorly described. FD in 
infancy can resemble juvenile idiopathic arthritis and a number of FD patients were originally 
diagnosed as having juvenile idiopathic arthritis (Sólyom et al. 2014; Torcoletti et al. 2014). 
Thus, it has been suggested that FD incidence may actually be higher, but that patients remain 
misdiagnosed as juvenile idiopathic arthritis. Diagnosis of FD is obtained by demonstration of 
reduced AC activity and/or abnormally high ceramide levels in cultured cells, biopsy samples 
or urine (Antonarakis et al. 1984; Ben-Yoseph et al. 1989; Dulaney et al. 1976; Fensom et al. 
1979; Kudoh and Wenger 1982; Levade et al. 1995; Sugita et al. 1975). Prenatal diagnosis is 
possible with amniocytes or chorionic villus samples (Fensom et al. 1979). 
Ceramide accumulation in FD occurs in the lysosomes (Levade et al. 1996; Sutrina and Chen 
1982; van Echten-Deckert et al. 1997). Whereas this may influence ceramide levels in other 
compartments over time, it explains why the reported ceramide-mediated signaling pathways, 
i.e. apoptosis, do not appear to be aberrantly regulated in FD, as these are mediated by plasma 
membrane ceramide (Segui et al. 2000; Tohyama et al. 1999). 
Currently, no cure for FD exists and treatment options are very limited. Some patients have 
been treated with allogenic haematopoetic stem cell transplantation with favorable results on 
joint manifestations (Ehlert et al. 2006; Torcoletti et al. 2014). However, this option is only 
suitable for patients without severe pulmonary disease and without neurological involvement 
(Yeager et al. 2000). The latter is also true for enzyme replacement therapy, which is currently 
being developed. Promising results from cell culture and mouse studies using the  
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recombinant human enzyme (rhAC) were recently reported (He et al. 2017). Still, the 
unsuitability of enzyme replacement therapy and hematopoietic stem cell transplantation for 
patients with neurological involvement means that there are essentially no treatment options for 
severely affected patients.  
2.4 Rheumatoid arthritis 
2.4.1 Background 
Rheumatoid arthritis (RA) is a chronic autoimmune disorder with an intermittent course and 
the most common inflammatory arthropathy. It is characterized by an inflammation of synovial 
joints, which progresses chronically and continuously and results in joint swelling and 
deformation, cartilage loss and bone erosions (Landre-Beauvais 1800). Often, RA leads to 
disability as it progresses. Inflammation in RA is not limited to the joints, but can also develop 
into a systemic disease with cardiovascular, pulmonary and skeletal involvement (Cojocaru et 
al. 2010). Cardiovascular disease due to chronic inflammation is among the main causes of 
death among RA patients (Dhawan and Quyyumi 2008). Worldwide, approx. 1 % of adults are 
affected and women have an approximately 3 times higher risk of developing RA then men 
(Silman and Pearson 2002). Some risk factors for RA have been identified. The underlying 
mechanisms, however, remain incompletely understood.  
 
2.4.2 Pathophysiology of rheumatoid arthritis 
2.4.2.1 Genetic and environmental factors 
Although the etiology is still unclear, both genetic and environmental risk factors have been 
identified in RA. One postulated mechanism is molecular mimicry, i.e. that sequence 
similarities between foreign and self-peptides result in a cross-activation of T lymphocytes or 
autoantibody production. An autoantibody commonly found in RA is anti-citrullinated protein 
antibody (ACPA). ACPA recognizes several citrullinated self-proteins, including α-enolase, 
keratin, fibrinogen, fibronectin, collagen and vimentin. ACPA production in patients has been 
associated with a common amino acid motif (QKRAA) in the human leucocyte antigen DR 
beta 1 (HLA-DRB1) gene region, the major genetic risk factor for RA (Gourraud et al. 2007). 
Additionally, ACPA seems to link genetic and environmental risk factors, since for instance 
smoking and HLA-DRB1 alleles synergistically increase one’s risk of having ACPA 
(Lundstrom et al. 2009) and seropositivity for citrullinated α-enolase and vimentin yielded the 
strongest association of HLA-DRB1, protein tyrosine phosphatase non-receptor type 22 and 
smoking (Lundberg et al. 2013).  
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Viruses and bacteria, including Epstein-Barr virus, cytomegalovirus and Escherichia coli and 
their products have also been postulated to be linked to RA by molecular mimicry. During 
infection, the formation of immune complexes may also trigger the induction of rheumatoid 
factor (RF), a high-affinity autoantibody against the Fc portion of immunoglobulin and a 
diagnostic marker of RA. Periodontal disease increases the risk of RA through Porphyromonas 
gingivalis (P. gingivalis) peptidylarginine deiminase: The enzyme citrullinates bacterial 
proteins, but also host fibrinogen and α-enolase and thus provides a basis for autoantibody 
production (Rosenstein et al. 2004; Wegner et al. 2010). Additionally, specific bacterial 
signatures in the gut microbiome are emerging, that are also being associated with autoantibody 
production (Scher and Abramson 2011).  
Environmental factors, such as smoking, may exert their effect through epigenetic 
modifications. Several such associations have been reported in RA: Alterations in DNA 
methylation, histone modifications and microRNA expression in immune and stromal cells 
influence key inflammatory and matrix-degrading pathways in RA (Messemaker, Huizinga, 
and Kurreeman 2015).  
Despite all of these identified associations, critical issues remain unresolved: Autoantibodies 
such as RF and ACPA are not detected in all patients and the systemic loss of tolerance does 
not fit to the localized onset of inflammation in the joints.  
 
2.4.2.2 Synovial inflammation 
Synovial inflammation (“synovitis”) results from leukocyte infiltration into the joint, rather 
than from local proliferation. Endothelial activation is thought to occur in synovial 
microvessels, resulting in an upregulation of adhesion molecules and chemokines and thus 
enabling cell recruitment into the joint (McMurray 1996). Platelets appear to help with this 
recruitment by adhering to the endothelium and releasing proinflammatory mediators and/or by 
providing a matrix for leukocyte adherence in a P-selectin dependent manner (Schmitt-Sody, 
Metz, Gottschalk, et al. 2007; Schmitt-Sody, Metz, Klose, et al. 2007).  
Adaptive immunity appears to be at the center of early RA pathogenesis. The relationship 
between HLA-DRB1 and disease severity suggests an important role for T cells in RA. T cells 
are abundant in the synovial milieu and the RA synovium contains abundant myeloid cells, 
plasmacytoid dendritic cells, HLA class II molecules, stimulatory cytokines and other 
costimulatory molecules required for T-cell activation (Lebre et al. 2008; Schröder et al.  
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1996). After activation, T cells promote synovial inflammation through secretion of pro-
inflammatory cytokines, but also through the support of B-cell activation and direct activation 
of innate immune cells, chondrocytes and osteoclasts. The later results in cartilage loss and 
bone erosion (McInnes, Buckley, and Isaacs 2016).  
Although conventionally Th1 helper cells are considered the key players in RA, the focus is 
now shifting towards the role of Th17 cells: The cytokine milieu in RA (Transforming growth 
factor ß (TGFß), Tumor necrosis factor α (TNF-α) and Interleukins (IL)-1ß, -6, -21 and -23) 
shifts T cell hemostasis towards inflammation by supporting Th17 differentiation and regulatory 
T cell suppression. Hence, the Th17 cytokine IL-17 is currently being targeted in clinical trials 
(Genovese et al. 2014). Similar to the suppression of regulatory T cells, the differentiation into 
Th2-like effector cells, which would produce anti-inflammatory cytokines, also appears to be 
suppressed in RA.  
B cells are also integral to RA pathogenesis. The presence of T-cell-B-cell aggregates in the 
synovium and other observations suggest ongoing T-cell-promoted, local production of 
autoantibodies by plasma cells in the synovium and juxta-articular bone marrow (Ohata et al. 
2005; Seyler et al. 2005). But the role of B cells in RA also goes beyond autoantibody 
production and includes autoantigen presentation and cytokine production (e.g. IL-6, TNF-α 
and lymphotoxin-ß) (Edwards et al. 2004).  
The innate immune system is also represented in synovial inflammation. Macrophages, in 
particular, are central effectors in RA, by releasing cytokines (e.g. TNF-α, IL-1, IL-6, IL-12, 
IL-15, IL-18 and IL-23), reactive oxygen- and nitrogen species (ROS, RNS) and matrix-
degrading enzymes, as well as by phagocytosis and antigen presentation (Haringman et al. 
2005).  
 
2.4.2.3 Key cytokines in rheumatoid arthritis 
Cytokines play an important role in the pathogenesis of RA by mediating inflammation and 
joint destruction. Therefore, several anti-cytokine agents have been developed for the treatment 
of RA targeting TNF-α, IL-1, IL-6 and more recently also IL-17 (Cohen et al. 2002; Elliott et 
al. 1993; Hueber et al. 2010; Yoshizaki et al. 1998). 
TNF-α is one of the main cytokines to result in inflammation during RA. It is released from 
activated macrophages, but also monocytes, fibroblasts, mast cells and natural killer (NK) cells. 
Locally, TNF-α stimulates the proliferation and differentiation of lymphocytes and NK  
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cells, promotes the production of other pro-inflammatory cytokines, e.g. IL-1 and IL-6, and 
induces the upregulation of adhesion molecules by fibroblasts. TNF-α is also elevated in the 
serum of RA patients, increasing the chances of cardiovascular disease through hypothalamic-
pituitary-adrenal axis dysregulation (O'Connor, O'Halloran, and Shanahan 2000). Surprisingly, 
recent data also identified some anti-inflammatory effects of TNF-α (Masli and Turpie 2009; 
Yang et al. 1994).  
IL-1ß is another pro-inflammatory and pro-erosive driver. It increases cytokine-, chemokine-, 
inducible NO synthase (iNOS)- and matrix metalloproteines (MMPs) secretion by synovial 
fibroblasts, as well as osteoclast activation and expression of adhesion molecules on the 
endothelium (McInnes, Buckley, and Isaacs 2016).  
IL-6 contributes to inflammation and joint destruction through activation of neutrophils, which 
then secrete ROS and proteolytic enzymes, and stimulation of osteoclast differentiation. 
Synergistically with TNF-α and IL-1ß, it enhances the production of vascular endothelial 
growth factor (VEGF) to establish and maintain the pannus, i.e. the vascular fibrous tissue that 
expands over the joint surface in RA (Dayer and Choy 2010). Systemically, increased IL-6 
levels in the blood of RA patients are associated with an increased risk of myocardial infarction 
(Yoshida and Tanaka 2014).  
The main source of IL-17 are Th17 cells, although some other cell types can also produce this 
cytokine. IL-17 increases the production of metalloproteinases, but also of pro-inflammatory 
cytokines, including again TNF-α, IL-1ß and IL-6 (McInnes, Buckley, and Isaacs 2016). 
Similarly to these, IL-17 also increases iNOS secretion and osteoclast stimulation. Moreover, 
IL-17 enhances the recruitment of further immune cells by stimulating chemokine production, 
e.g. C-X-C motif chemokine ligand 5 and 12 (CXCL5 and CXCL12) and by promoting 
neovascularization (Honorati et al. 2006; Kim et al. 2007). Suppression of IL-17 successfully 
reduced arthritis severity in experimental models (Gaffen 2009; Koenders et al. 2005; Sarkar et 
al. 2009).  
In the experimental model of antigen-induced arthritis, which is employed as a model for 
inflammatory arthritis in this study, IL-6 and IL-1ß appear to be the driving cytokines, whereas 
TNF-α only increases mildly (Simon et al. 2001). Moreover, knock-out of TNF-α in mice 
conferred less protection from arthritis than IL-6 deficiency (Wong et al. 2006; Yokomatsu et 
al. 2003).   
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2.4.3 Treatment of rheumatoid arthritis 
2.4.3.1 Disease modifying anti-rheumatic drugs 
Historically, RA was treated with intramuscular (i.m.) injection of gold (Forestier 1932), 
because it was believed that RA had an infectious etiology and Koch had demonstrated the 
antimicrobial properties of gold cyanide in 1890. How gold salts actually reduce arthritis 
severity is unknown. In vitro studies suggested that gold works by interfering with lymphocyte 
and monocyte function, but in vivo studies do not support this. Thus, it is unclear how gold 
decreases the levels of immune complexes and RF (Klinefelter and Achurra 1973). Today, gold 
is no longer recommended for the treatment of RA due to high rate of adverse effects (approx. 
33 %), potentially serious toxic effects (e.g. nephrotic syndrome, cytopenias, interstitial lung 
disease, peripheral neuropathies) and low response rates (only about 1/3 of patients achieve 
good clinical and radiographic responses) (Zampeli, Vlachoyiannopoulos, and Tzioufas 2015).  
The first drug specifically synthesized for RA is Sulfasalazine (SSZ). Due to the idea that RA 
was caused by bacterial infections, which still prevailed at the time, the antibiotic sulfapyridine 
was linked to a complex saliacylic acid. SSZ effects T and B-cell populations and suppresses 
levels of IL-1 and TNF-α (Danis et al. 1992). Despite initially favorable results in open trials 
and a similar efficacy as i.m. gold and potentially also methotrexate, with less severe toxicity 
then both, SSZ therapy was discontinued.  
The introduction of glucocorticoids (GCs) in the 1950 was originally hailed as the cure for RA. 
GCs do rapidly, reliably and effectively suppress synovitis and RA symptoms. Due to their 
devastating side effects at high and long-term doses, they are only used as a low-dose therapy 
today and even this is controversial (Saag 1997). The recommendation is to use GCs at the 
lowest possible dose for the shortest possible period of time to achieve the treatment goals (van 
der Goes et al. 2010).  
Also in the 1950’s, methotrexate (MTX) was shown to be effective in RA (Gubner, August, 
and Ginsberg 1951). It did not become the gold-standard of care until after the initial excitement 
over GCs had passed and the FDA approved treatment for RA in 1988. Originally developed 
as an anticancer drug, MTX is a folic acid analogue, that inhibits purine and pyrimidine 
synthesis and thus acts as a cytostatic agent. At the doses given for RA, however, MTX is 
minimally immunosuppressive. Thus, other mechanisms have been suggested, including 
inhibition of angiogenesis (Hirata et al. 1989). Mostly, adverse events due to MTX treatment 
are minor and can be managed without discontinuation of the drug. The potential  
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toxicity, however, is severe and may cause cytopenias, hepatotoxicity with subsequent fibrosis 
and cirrhosis, as well as pulmonary interstitial disease with subsequent fibrosis. For the later, 
the incidence may be up to 3-5 % (Zitnik and Cooper 1990). MTX is also abortifacient and 
teratogenic. Leflunomide, an inhibitor of de novo pyrimidine synthesis, is emerging as an 
alternative to MTX with similar efficacy but potentially better toxicity/tolerability profile (Xu 
et al. 1997).  
Some more disease modifying anti-antirheumatic drugs (DMARDs) have been used clinically 
at some point. None have established themselves to a similar extent as MTX due to low efficacy 
(e.g. D-pencillamine and the antimalarials chloroquine and hydroxychloroquine) (Faarvang et 
al. 1993; Ferraz et al. 1994) or toxicity concerns (e.g. Cyclosporine A) (Case 2001). Thus, future 
advances are expected with biologic therapies rather than with classical DMARDs.  
 
2.4.3.2 Novel therapeutic strategies in rheumatoid arthritis 
Several new treatment options are in clinical development for the treatment of RA. 
Unsurprisingly, classical RA-cytokines were among the first new therapeutic targets. Anti-TNF 
biologics and anti-IL-6 receptor antibody have been shown to effectively control disease 
activity and prevent articular damage in RA, while anti-IL-17 antibodies, an anti-IL-21 and an 
anti-GM-CSF antibody are still being tested (Semerano et al. 2016).  
The opposite route – delivering anti-inflammatory cytokines rather than blocking pro-
inflammatory ones – is also being tried: Dekavil targets anti-inflammatory IL-10 to the joints 
by fusion with an anti-fibronectin antibody. IL-10 is an important suppressor of cytokine 
formation, including TNF-α, IL-1ß and IL-6. It also inhibits antigen-presentation by 
macrophages and MMP production (Mottonen et al. 1998). Dekavil obtained promising Phase 
1b-trial results (Galeazzi et al. 2014).  
The anti-CD20 antibody rituximab has already been approved for the treatment of RA. Next to 
depletion of all CD20-expressing B cells, rituximab has also been found to induce CD4+ T cell 
depletion (Melet et al. 2013). Other antibodies against B-cell surface molecules, however, have 
been discontinued due to safety issues (Quattrocchi et al. 2016; Weinblatt et al. 1995).  
Thus far, the targeting of cell-matrix interactions, ectopic lymphoid neogenesis, stromal cells, 
Th17 differentiation, IL-17 receptor and the use of a non-depleting anti-CD4 antibody to induce 
tolerance have not yet achieved clinical efficacy (Semerano et al. 2016).  
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Targeting of intracellular signaling pathways in RA by small molecule kinase inhibitors are 
also being attempted: P38 mitogen-activated protein kinase (MAPK) inhibitors have already 
failed clinical development, probably due to redundant MAPK pathways (Genovese 2009). 
Similarly, the spleen-tyrosine kinase inhibitor Fostamatinib was also not pursued further 
(Kunwar, Devkota, and Ghimire 2016). A Bruton’s tyrosine kinase inhibitor is currently 
undergoing a phase II study (Chang et al. 2011). One Janus kinase inhibitor, Tofacitinib, is 
already marketed in the US for RA, two (Decemotinib and Baricitinib) are currently in a 
Phase III study and two others (Filgotinib and ABT-494) have achieved significant clinical 
responses in phase IIb studies (Genovese et al. 2016; Kremer, Genovese, et al. 2016; Kremer, 
Emery, et al. 2016; Van Rompaey et al. 2013; Westhovens et al. 2016).  
 
 
Figure 5: Novel therapeutic targets in rheumatoid arthritis – Monoclonal antibodies have been developed 
against T- and B- cell cytokines, the major new therapeutic targets. Small-molecule inhibitors of intracellular 
kinases are also being tested, as well as cell-directed treatments such as low dose IL-2 or T cell superagonists 
like CD28Sag. Current therapeutics are noted by red boxes, potential future therapeutic targets by blue boxes 
(Semerano et al. 2016). 
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2.5 Aim of the study 
The overall goal of this study was to expand the existing applications of known ASM inhibitors 
to new ASM/ceramide-related diseases with a currently unmet clinical treatment need. FD and 
RA were chosen because of the potential implication of ASM/ceramide in the pathogenesis of 
these diseases and the high demand for new treatment strategies.  
Concerning FD, the accumulation of lysosomal ceramide is the cause of the disease. Thus, the 
hypothesis arose that ceramide accumulation may be prevented by blocking lysosomal 
generation of ceramide with ASM inhibitors and the ceramide accumulation may thus 
redistribute upstream to less toxic lipids (Fig. 5). Indications that such an approach would be 
advantageous came from CF clinical trials, in which the pulmonary ceramide accumulation 
present in CF patients was successfully targeted with the ASM inhibitor Amitriptyline (Adams 
et al. 2016; Teichgräber et al. 2008). 
An accurate assessment of the efficacy of such a treatment for FD cannot be obtained in in 
vitro-models alone and thus requires an experimental model of FD. Our group generated a 
viable Ac-KO mouse model for the study of FD – one of only two FD animal models 
worldwide. This study first characterizes the Ac-KO phenotype to assess its utility as a model 
for the human disease. Next, a double knock-out mouse was generated by co-ablation of Asm. 
The phenotype assessment of the double mutants serves as a proof-of-concept study to assess 
the efficacy of Asm inhibition as a treatment for FD. The FD part of this study concludes with 
the pharmacological treatment of Ac-KO mice with functional Asm inhibitor Amitriptyline.  
 
Figure 6: Rescue strategy – Under physiological conditions, ASM catalyzes the hydrolysis of sphingomyelin 
to ceramide and AC de-acetylates ceramide to sphingosine. In FD, deficiency in AC results in ceramide 
accumulation. The hypothesis tested in this study is that co-depletion of ASM may prevent ceramide 
accumulation and thus ameliorate FD symptoms.  
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The second part of this thesis addresses the role of ASM/ceramide in RA. A few reports already 
exist implicating ASM and/or ceramide in autoimmunity: Yang and coworkers demonstrated 
an important role for ASM in mast cell function (Yang et al. 2014). Studies on inflammatory 
bowel disease report an increase of ceramide combined with an induction of MMP-1 in a 
chronic colitis model, which could be blocked with the FIASMA Imipramine (Bauer et al. 
2009). MMP1 has a rate-limiting role in RA as well, because it degrades articular collagen 
(Burrage, Mix, and Brinckerhoff 2006). In multiple sclerosis, Asm-KO mice were shown to be 
protected from a murine model of the disease (Verderio et al. 2012) and an in vitro study 
reported that endothelial ASM regulates T cell transmigration across brain endothelial cells via 
intracellular adhesion molecule-1 (Lopes Pinheiro et al. 2016). In RA itself, ceramide is 
increased in the synovial fluid of RA patients (Kosinska et al. 2014).  
Due to these links between ASM/ceramide and autoimmunity, the susceptibility of Asm-KO 
mice was assessed in an experimental model of inflammatory arthritis – murine antigen-induced 
arthritis (AIA) – in the present study.  
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3. Materials and Methods 
3.1 Materials 
3.1.1 Chemicals 
Acetic acid (100 %) Merck KGaA, Darmstadt, Germany 
Acrylamide Carl-Roth GmbH & Co, Karlsruhe, Germany 
Amitriptyline hydrochloride  
(≥ 98 %) 
Sigma-Aldrich Chemie GmbH, Steinheim, Germany 
Ammonium persulfate (APS) Carl-Roth GmbH & Co, Karlsruhe, Germany 
Aprotinin Roche Deutschland Holding GmbH, Freiburg, Germany 
BODIPY-sphingomyelin Thermo Fisher Scientific, Waltham, MA, USA 
Bovine serum albumin (BSA), 
fatty acid free 
Sigma-Aldrich Chemie GmbH, Steinheim, Germany 
Bradford Protein assay Biorad Laboratories GmbH, München, Germany 
Bromphenol blue Sigma-Aldrich Chemie GmbH, Steinheim, Germany 
Calcium chloride (≥ 99 %) Carl-Roth GmbH & Co, Karlsruhe, Germany 
Carbon dioxide (CO2) AIR LIQUIDE Medical GmbH, Düsseldorf, Germany 
Chloroform AppliChem GmbH, Darmstadt, Germany 
Complete Freud’s adjuvant 
(CFA) 
Sigma-Aldrich Chemie GmbH, Steinheim, Germany 
Complete protease inhibitor 
cocktail 
Roche Deutschland Holding GmbH, Freiburg, Germany 
Dabco Sigma-Aldrich Chemie GmbH, Steinheim, Germany 
Decalcifier soft Carl-Roth GmbH & Co, Karlsruhe, Germany 
Di-potassium hydrogen 
phosphate 
Carl-Roth GmbH & Co, Karlsruhe, Germany  
Di-sodium hydrogen phosphate Merck KGaA, Darmstadt, Germany 
Eosin Carl-Roth GmbH & Co, Karlsruhe, Germany 
Ethanol (absolute, anhydrous) Diagonal GmbH & Co. KG, Münster, Germany 
Ethyl acetate Diagonal GmbH & Co. KG, Münster, Germany 
FastGreen Carl-Roth GmbH & Co, Karlsruhe, Germany 
FITC-Phalloidin Sigma-Aldrich Chemie GmbH, Steinheim, Germany 
Glucose Sigma-Aldrich Chemie GmbH, Steinheim, Germany 
Glycerol (≥ 99 %) Carl-Roth GmbH & Co, Karlsruhe, Germany 
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Hematoxylin Carl-Roth GmbH & Co, Karlsruhe, Germany 
HEPES Carl-Roth GmbH & Co, Karlsruhe, Germany 
Hydrochloric acid  
(fuming, 37 %) 
Sigma-Aldrich Chemie GmbH, Steinheim, Germany 
Isoflurane (Isothesia) Henry Schein Vet GmbH, Hamburg, Germany 
Leupeptin Becton, Dickinson GmbH, Heidelberg, Germany  
Liquid Nitrogen AIR LIQUIDE Medical GmbH, Düsseldorf, Germany 
Magnesium chloride 
hexyhydrate (≥ 99 % p.a.) 
Carl-Roth GmbH & Co, Karlsruhe, Germany 
Magnesium sulfate heptahydrate 
(≥ 99 %) 
Sigma-Aldrich Chemie GmbH, Steinheim, Germany 
Manganese chloride Sigma-Aldrich Chemie GmbH, Steinheim, Germany 
Methanol (≥ 99.8 %) Diagonal GmbH & Co. KG, Münster, Germany 
Methylated bovine serum 
albumin (mBSA) 
Sigma-Aldrich Chemie GmbH, Steinheim, Germany 
Mowiol-488 Hoechst GmbH, Frankfurt, Germany 
NBD-ceramide Thermo Fisher Scientific, Waltham, MA, USA 
NP-40 (Igepal) Sigma-Aldrich Chemie GmbH, Steinheim, Germany 
Paraformaldehyde  
(powder, 95 %) 
Sigma-Aldrich Chemie GmbH, Steinheim, Germany 
Paraplast Leica Mikrosysteme Vertrieb GmbH, Wetzlar, Germany 
Perm/Wash buffer Becton, Dickinson GmbH, Heidelberg, Germany 
Polyoxyethyle glycol sorbitan 
monolaurate (Tween20) 
Sigma-Aldrich Chemie GmbH, Steinheim, Germany 
Potassium chloride (≥ 99 %) Carl-Roth GmbH & Co KG, Karlsruhe, Germany 
Propidium iodide (95-98 %) Sigma-Aldrich Chemie GmbH, Steinheim, Germany 
SafraninO Carl-Roth GmbH & Co KG, Karlsruhe, Germany 
Sodium chloride (≥ 99,5 %) Carl-Roth GmbH & Co KG, Karlsruhe, Germany 
Sodium citrate  
(tribasic, dehydrate) 
Sigma-Aldrich Chemie GmbH, Steinheim, Germany 
ß-Mercaptoethanol Sigma-Aldrich Chemie GmbH, Steinheim, Germany 
Starting Block TBS Blocking 
Solution 
Thermo Fisher Scientific, Waltham, MA, USA 
Xylene (mixture of isomers) Diagonal GmbH & Co. KG, Münster, Germany 
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3.1.2 Antibodies 
AC, ß-unit (goat-anti-mouse) SantaCruz Biotechnology, Inc., Dallas, TX, USA 
CD127 (IL-7Rα)-PE-Cy7  
(anti-mouse) 
Biolegend, San Diego, CA, USA 
CD27-biotin (anti-mouse) Biolegend, San Diego, CA, USA 
CD44-APC (anti-mouse) Becton, Dickinson GmbH, Heidelberg, Germany 
CD45-PE (anti-mouse) Thermo Fisher Scientific, Waltham, MA, USA 
CD45R/B220-APCeFluor780  
(anti-mouse) 
Thermo Fisher Scientific, Waltham, MA, USA 
CD4-PacificBlue (anti-mouse) Becton, Dickinson GmbH, Heidelberg, Germany 
CD62L-PE (anti-mouse) Becton, Dickinson GmbH, Heidelberg, Germany 
CD8-APCeF780 (anti-mouse) Thermo Fisher Scientific, Waltham, MA, USA 
CD95-PE-Cy7 (anti-mouse) Becton, Dickinson GmbH, Heidelberg, Germany 
GL7-AF488 (anti-mouse) Thermo Fisher Scientific, Waltham, MA, USA 
HRP-coupled anti-beta-actin SantaCruz Biotechnology, Inc., Dallas, TX, USA 
HRP-coupled secondary antibodies Cell Signaling Technology, Danvers, MA, USA 
IgG1-PE (anti-mouse) Becton, Dickinson GmbH, Heidelberg, Germany 
IgG-AF488 (goat anti-mouse) Thermo Fisher Scientific, Waltham, MA, USA 
IgG-AF647 (donkey-anti-rat) Jackson ImmunoResearch Europe Ltd., Suffolk, UK 
IgG-Cy3 (donkey-anti-goat) Jackson ImmunoResearch Europe Ltd., Suffolk, UK 
IgM-APC (anti-mouse) Becton, Dickinson GmbH, Heidelberg, Germany 
LAMP-1 (rat-anti-mouse) Abcam PLC, Cambridge, UK 
ß1-Integrin, activated (clone 
HUTS4, mouse anti-human) 
Merck KGaA, Darmstadt, Deutschland 
Steptavidin-FITC Becton, Dickinson GmbH, Heidelberg, Germany 
TCRb-PerCP-Cy5.5 (anti-mouse) Thermo Fisher Scientific, Waltham, MA, USA 
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3.1.3 Kits, panels and enzymes 
Bacterial Sphingomyelinase  
(from Bacillus cereus) 
Sigma-Aldrich Chemie GmbH, Steinheim, 
Germany 
BrdU cell proliferation ELISA 
(colorimetric) kit 
Roche Deutschland Holding GmbH, Freiburg, 
Germany 
Creatinine (serum) colorimetric assay kit Biomol GmbH, Hamburg, Germany 
ECL prime system GE Healthcare Europe GmbH, Freiburg, 
Germany 
Glucose (urinary) colorimetric assay kit Biomol GmbH, Hamburg, Germany 
IL-10 (mouse) Quantikine ELISA R&D Systems Inc., Minneapolis, MN, USA 
IL-17 (mouse) Quantikine ELISA R&D Systems Inc., Minneapolis, MN, USA 
IL-1ß (mouse) Quantikine ELISA R&D Systems Inc., Minneapolis, MN, USA 
IL-2 (mouse) Quantikine ELISA R&D Systems Inc., Minneapolis, MN, USA 
IL-4 (mouse) Quantikine ELISA R&D Systems Inc., Minneapolis, MN, USA 
IL-6 (mouse) Quantikine ELISA R&D Systems Inc., Minneapolis, MN, USA 
Insulin ELISA kit Thermo Fisher Scientific, Waltham, MA, USA 
Masson trichrome staining kit Sigma-Aldrich Chemie GmbH, Steinheim, 
Germany 
MCP-1 (mouse) Quantikine ELISA R&D Systems Inc., Minneapolis, MN, USA 
Mouse regulatory T cell staining kit #1  Thermo Fisher Scientific, Waltham, MA, USA 
RotiLumin system Carl-Roth GmbH & Co, Karlsruhe, Germany 
Spotchem parameter strips Scil animal care company GmbH, Viernheim, 
Deutschland 
ß-hydroxybutyrate colorimetric assay kit Biomol GmbH, Hamburg, Germany 
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3.1.4 Media and additives 
DMEM Thermo Fisher Scientific, Waltham, MA, USA 
FBS GE Healthcare Europe GmbH, Freiburg, Germany 
Histopaque-1077 Sigma-Aldrich Chemie GmbH, Steinheim, Germany 
Horse serum Thermo Fisher Scientific, Waltham, MA, USA 
IL-2 (human) R&D Systems Inc., Minneapolis, MN, USA 
IL-2, mouse Thermo Fisher Scientific, Waltham, MA, USA 
IMDM Thermo Fisher Scientific, Waltham, MA, USA 
L-Glutamine Thermo Fisher Scientific, Waltham, MA, USA 
Non-essential amino acids Thermo Fisher Scientific, Waltham, MA, USA 
PenStrep Thermo Fisher Scientific, Waltham, MA, USA 
Phytohaemagglutinin (PHA) P Sigma-Aldrich Chemie GmbH, Steinheim, Germany 
RPMI 1640 (1x, [+] L-Glutamine) Thermo Fisher Scientific, Waltham, MA, USA 
Sodium pyruvate Thermo Fisher Scientific, Waltham, MA, USA 
TNF-α, mouse recombinant R&D Systems Inc., Minneapolis, MN, USA 
 
3.1.5 Prepared buffers and solutions 
Ac/Asm assay buffer 250 mM sodium acetate 
0.1 % NP-40 
pH 4,5 (Ac) or pH 5,0 (Asm) 
Ac/Asm lysis buffer 250 mM sodium acetate 
1 % NP-40 
pH 4,5 (Ac) or pH 5,0 (Asm) 
Ac/Asm substrate solution 1 µl NBD-Cer 
27.2 mL Ac assay buffer 
Asm substrate solution 0,5 µl BODIPY-Sphingomyelin 
1 mL Asm assay buffer 
HEPES/Saline (HS) (10x) 200 mM HEPES 
1.32 M NaCl 
10 M CaCl2 
7 mM MgCl2 
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8 mM MgSO4 
54 mM KCl 
Mowiol 20-25 % Mowiol-488 
2,5 % Dabco 
Paraformaldehyde (PFA), 4 %  4 % PFA 
1 x PBS 
pH 7,2 – 7,4 adjusted with HCl and NaOH 
Phosphate buffered saline (PBS) 137 mM NaCl 
2.7 mM KCl 
10 mM Na2HPO4 • 2 H20 
2.0 mM KH2PO4 
pH adjusted with HCl and NaOH  
Reducing SDS sample buffer (5x) 250 mM Tris pH 6.8 
20 % Glycerine 
4 % SDS 
8 % ß-mercaptoethanol 
0.2 % bromphenol blue 
SDS lysis buffer, 0.1 % 25 mM HEPES, pH 7,3 
0.1 % sodium dodecyl sulfate 
0.5 % sodium deoxycholate 
1 % Triton-X-100 
125 mM NaCl 
10 mM NaF 
10 mM Na2P2O7 
20 mM Na3VO4 
10 mM ethylenediaminetetraacetic acid 
10 µg/ml aprotinin 
10 µg/ml leupeptin 
1 x Roche Complete protease inhibitor cocktail  
SDS Running buffer 25 mM Tris 
192 mM glycine 
0.1 % SDS 
Tris/0.1 % Tween-20 20 mM Tris 
150 mM NaCl 
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0.1 % Tween-20 
 
Tyrode’s buffer 
 
134 mM NaCl 
0.34 mM Na2HPO4 
2,9 mM KCl 
12 mM NaHCO3 
20 mM HEPES 
5 mM Glucose 
pH adjusted to pH 7,1 
 
3.1.6 Consumables 
Cathether  
(Vasofix Safety 18 G x 1 ¾’’) 
B. Braun Melsungen AG, Melsungen, Germany 
Cell culture flasks Sarstedt AG & Co, Nümbrecht, Germany 
Cell strainer (70 µm)  Corning Inc., New York, NY, USA 
Centrifuge tubes (15 mL, 50 mL) Greiner Bio-One GmbH, Frickenhausen, Germany 
Coverglass (18 x 18 mm) Engelbrecht GmbH, Wien, Austria 
Coverslips (Ø 12 mm) Carl-Roth GmbH & Co, Karlsruhe, Germany 
Cuvettes Sarstedt AG & Co, Nümbrecht, Germany 
EDTA collection tubes Greiner Bio-One GmbH, Frickenhausen, Germany 
Embedding cassettes Carl-Roth GmbH & Co, Karlsruhe, Germany 
Hybond ECL nitrocellulose membrane GE Healthcare Europe GmbH, Freiburg, Germany 
Hypodermic needle Becton Dickinson GmbH, Heidelberg, Germany 
Microscopic slides Langenbringen Labor- und Medizintechnik, 
Emmendingen, Germany 
Microtiter plates Sarstedt AG & Co, Nümbrecht, Germany 
Needles (different gauges) Becton Dickinson GmbH, Heidelberg, Germany 
NH4-Heparin collection tubes Sarstedt AG & Co, Nümbrecht, Germany 
Pipettes (5 mL, 10 mL, 25 mL) Greiner Bio-One, Frickenhausen, Germany 
Reaction tubes, 1.5 mL Sarstedt AG & Co, Nümbrecht, Germany 
Reaction tubes, 2 mL Eppendorf AG, Hamburg, Germany 
Stainless steel beads, 5 mm Qiagen GmbH, Hilden, Germany 
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Syringes 
- Insulin syringe 
- Luer-lock 1 mL syringe 
- Rubber- and lubricant free 
 
 
 
Becton Dickinson GmbH, Heidelberg, Germany 
Becton Dickinson GmbH, Heidelberg, Germany 
Sigma-Aldrich Chemie GmbH, Steinheim, 
Germany 
Thin layer chromatography (TLC) 
Silica G60 plates 
Merck KGaA, Darmstadt, Germany 
X-Ray films GE Healthcare Europe GmbH, Freiburg, Germany 
 
3.1.7 Equipment 
Centrifuges 
- 5417 R 
- Heraeus 3SR+ multifuge 
 
Eppendorf AG, Hamburg, Germany 
Thermo Fisher Scientific, Waltham, MA, USA 
Clean bench  
(biological safety cabinet class II) 
NuArie, Plymouth, MN, USA 
Microscopes 
- confocal fluorescence 
(TCS-SP5) 
- fluorescence 
(BIOREVO B2-9000) 
 
Leica Mikrosysteme Vertrieb GmbH, Wetzlar, 
Germany 
Keyence Deutschland GmbH, Neu-Isenburg, 
Germany 
Developer machine Thermo Fisher Scientific, Waltham, MA, USA 
Digital caliper Mitutoyo UK Ltd., Andover, UK 
Flow cytometer 
- Calibur 
- LSR III 
 
Becton, Dickinson GmbH, Heidelberg, Germany 
Becton, Dickinson GmbH, Heidelberg, Germany 
Freezers 
- 80 °C, ultra low MDF-U54V 
- 20 °C, Premium NoFrost 
 
Sanyo Electric Co, Osaka, Japan 
Liebherr-International Deutschland GmbH, 
Biberach, Deuschland  
Fridge (4 °C, Premium BioFresh) Liebherr-International Deutschland GmbH, 
Biberach, Germany 
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Glasswares  
(beakers, cylinders, flasks) 
DURAN Group GmbH, Wertheim, Germany 
Incubator Binder GmbH, Tuttlingen, Germany 
Infrared lamp Philips Consumer Lifestyle B.V., Drachten, The 
Netherlands 
Magnetic stirrer (M21) Intern. Laborat. App GmbH, Dottingen, Germany 
Mass spectrometer (Q-TOF 6530) Agilent Technologies, Waldbronn, Germany 
Mechanical shaker (Rotamax120) Heidolph Instruments GmbH & Co. KG, 
Schwabach, Germany 
Microtome Thermo Fisher Scientific, Waltham, MA, USA 
pH Meter (HI9025) Hanna instruments, Woonsocket, RI, USA 
Pipettes (different sizes) Nichiryo CO., Ltd., Saitama, Japan 
Pipettus (pipetus-akku) Hirschmann Laborgeräte GmbH und Co. KG, 
Eberstadt, Germany 
Rotary microtome  
(Microm HM 3555) 
Thermo Scientific, Waltham, MA, USA 
Spectrophotometer  Eppendorf AG, Hamburg, Germany 
SpeedVac Thermo Fisher Scientific, Waltham, MA, USA 
SpotChem EZ chemistry analyser Scil animal care company GmbH, Viernheim, 
Deutschland 
Thermomixer Eppendorf AG, Hamburg, Germany 
TissueLyser Qiagen GmbH, Hilden, Germany 
Typhoon FLA 9500 GE Healthcare Europe GmbH, Freiburg, Germany 
Ultrasonic bath (sonorex RK 102 H) BANDELIN electronic GmbH & Co. KG, Berlin, 
Germany  
Vacuum concentrator (SpeedVac)  Bachofer GmbH, Reutlingen, Germany 
VetABC Scil animal care company GmbH, Viernheim, 
Deutschland 
Vortexer (Reax 2000) Heidolph Instruments GmbH & Co. KG, 
Schwabach, Germany 
Water bath (1o12) GFL Gesellschaft für Labortechnik mbH, 
Burgwedel, Germany 
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3.1.8 Software 
GraphPad Prism (5.01) GraphPad Software, La Jolla, CA, USA 
ImageQuant GE Healthcare Europe GmbH, Freiburg, Germany 
Leica advanced Fluorescence – 
Application Suite (2.61) 
Leica Mikrosysteme Vertrieb GmbH, Wetzlar, 
Germany 
MassHunter Software Agilent Technologies, Waldbronn, Germany 
Microsoft Office (2016) Microsoft Corporation, Redmond, WA, USA 
 
3.2 Methods 
3.2.1 Animal husbandry and animal procedures 
3.2.1.1 Animal husbandry 
All mice were maintained on the C57BL/6 Jackson background. Mice were bred and housed in 
the vivarium of the University Hospital Essen, Germany under pathogen-free conditions as 
defined by the Federations of European Laboratory Animal Science Associations (FELASA). 
The pathogen-free status was routinely assessed through a sentinel program. Mice had ad 
libitum access to food and water and were kept on a 12 h/12 h light/dark cycle. Genotypes were 
assessed by PCR. For antigen-induced arthritis experiments, only female mice were used. All 
procedures (subsequently described in detail) were approved by the State Agency for Nature, 
Environment and Consumer Protection (LANUV) NRW in Düsseldorf, Germany.  
 
3.2.1.2 Generation of the Asah1 knock-out mouse model 
A conditional Asah1 knock-out model was generated by GenOway (Lyon, France) through 
flanking Exon1 with loxP sites and removal of the neomycin selection cassette via crossing to 
Flp recombinase deleter mice. In detail, the Asah1 exon/intron organization was established 
based on the cDNA sequence NM_019734. A targeting vector was then constructed containing 
two homology regions to the Asah1 genomic sequence (one of 5.8 kb and one of 1.7 kb), two 
loxP sites flanking Asah1 Exon1, a neomycin cassette flanked by FRT sites for positive 
selection and a diphtheria toxin A negative-selection marker to enhance the isolation of ES cell 
clones containing also the distal loxP site. This targeting vector was inserted into C57BL/6 
embryonic stem cells by homologous recombination. The resulting chimeric mice were 
crossbred to C57BL/6 Flp deleter mice to remove the neomycin cassette and generate mice 
heterozygous for the Neo-excised conditional Asah1 kock-out allele. These mice were 
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subsequently crossed to a C57BL/6 EIIa-cre transgenic strain and the resulting offspring with 
the heterozygous excised allele was mated among each other to obtain the constitutive knock-
out model. Ac and Asm co-deficient mice were obtained by subsequent crossing of Asah1+/- 
mice to Smpd1+/- mice, which have been previously described in the literature (Horinouchi et 
al. 1995).  
 
3.2.1.3 Induction and assessment of antigen-induced arthritis 
mBSA was diluted at 10 mg/ml in 5 % Glucose, subsequently diluted further to 2 mg/ml in 5 % 
Glucose in PBS and emulsified 1:1 (v/v) with CFA (Sigma) using rubber- and lubricant free 
syringes (BD Bioscience). The emulsion was injected s.c. into the axillary and inguinal lymph 
node regions on day -21 and day -14 (4 x 50 µl/mouse) under anesthesia with isoflurane. 
Arthritis was induced on day 0 by injection of 10 µl 10 mg/ml mBSA in 5 % Glucose into one 
knee joint cavity through a 30 G needle. The contralateral joint was injected with the same 
volume 5 % Glucose. Intraarticular injections were also carried out under isoflurane-anesthesia. 
Knee joint diameter was assessed with a digital caliper immediately after induction and once 
daily on all subsequent days.  
 
Figure 7: Timeline of the antigen-induced arthritis model – Mice are immunized with mBSA emulsified in 
CFA s.c. on experimental day -21 and -14. On day 0. mBSA is injected directly into the joint cavity to induce 
arthritis.  
 
3.2.1.4 Platelet transplantation 
Donor mice were placed under an infrared lamp for 5 min for vasodilatation in the tail. 400 µl 
of blood were freshly collected via a tail vein incision. Collection tubes contained 0.38 % 
sodium citrate for anti-coagulation. The blood was supplemented with 9 mL PBS (pH 7.2) + 
3.5 % fatty acid free BSA (Sigma) and incubated for 15 min at 37 °C. Red blood cells and 
leukocytes were pelleted by centrifugation at 120 x g without brake for 20 min at room 
temperature. The platelet-rich supernatant was collected and the platelets were subsequently 
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pelleted by centrifugation at 1,340 x g for 10 min. Platelets were washed twice with Tyrode’s 
buffer to remove BSA. After the final wash, platelets were resuspended in 200 µl Tyrode’s 
buffer and injected via the tail vein into recipient mice 2 h prior to arthritis induction. Recipient 
mice were placed under infrared light for 5 min prior to the i.v. injection to help visualization 
of the tail vein.  
 
3.2.1.5 Amitriptyline treatment 
Arthritic mice were treated via i.p. injections: Amitriptyline was freshly diluted and injected at 
9.375 mg/kg bodyweight in 50 µl 0.9 % sodium chloride every 6 h. Treatment commenced 
2.5 days prior to arthritis induction and continued until the mice were sacrificed. The control 
group was injected with 50 µl 0.9 % sodium chloride.  
Ac deficient mice were treated with Amitriptyline via the drinking water. In one group, 
treatment was started shortly after weaning, when FD symptoms were still relatively mild. In 
the second group, the treatment was already started in utero to prevent ceramide from 
accumulating. The parents were mated for 4 days. The male was then removed from the cage 
and the female received 180 mg/l Amitriptyline in 0.9 % sodium chloride as drinking water. 
Fresh amitriptyline was prepared every second day. After birth, treatment of the mother was 
continued and after weaning, the offspring received the same dose of Amitriptyline in the 
drinking water directly.  
 
3.2.2 Biochemical and molecular methods 
3.2.2.1 Intracellular localization of Ac and the mutant protein 
Intracellular localization of Ac was assessed in mesenchymal stem cells isolated from wild-
type or Ac deficient mice as previously described (Peister et al. 2004). These cells were 
maintained in IMDM K10 + 10 % horse serum. The cells were seeded on coverslips in a 12-
well plate. Due to unequal proliferation rates, 2 x 104 wild-type cells/well were seeded and 
3 x 104 Ac deficient cells/well and then grown for 48 h. Cells were washed with H/S and then 
fixed for 15 min with ice-cold methanol at 4 °C for 15 min. Cells were then washed 3 x 5 Min 
with BD Perm/Wash, followed by 20 Min blocking in Perm/Wash supplemented with 5 % FCS. 
Cells were subsequently stained with the first primary antibody directed against the ß-unit of 
AC diluted in Perm/Wash + 1 % FCS.  The second primary antibody directed against the 
lysosomal marker protein LAMP-1 was added after 1 h for an additional 1 h incubation  
Materials and Methods 
 
45 
 
period. The coverslips were washed 3 x 5 min with BD Perm/Wash to remove any unbound 
primary antibody molecules and then stained with the corresponding secondary antibodies for 
1 h at room temperature. The coverslips were washed three times again and then mounted with 
Mowiol.  
 
3.2.2.2 Determination of Ac and Asm activity 
Ac and Asm activities were determined as recently described (Mühle and Kornhuber 2017). 
Mice were sacrificed by CO2 exposure and blood was drawn from the V. cava inferior into 
reaction tubes containing 50 µl 3.8 % sodium citrate to prevent coagulation. Plasma was 
collected after centrifugation for 10 min with 2,500 x g and snap-frozen in 2 mL reaction tubes 
with a 5-mm stainless steel bead (hereafter called TissueLyser tube). Bone marrow was flushed 
from both femurs and tibias into a 2 mL reaction tube using a syringe and large gauge needle 
filled with 1 ml PBS. Cells were pelleted by 5 min centrifugation at 300 x g and the supernatant 
was removed. A 5-mm stainless steel bead was added and samples were snap-frozen. Lymph 
nodes and thymus were dissected and snap-frozen in TissueLyser tubes. The other organs were 
dissected, snap-frozen and pulverized using a mortar and pestle filled with liquid nitrogen. A 
generous scoop of the organ powder was transferred to pre-cooled TissueLyser tube on dry ice. 
Samples were incubated at room temperature for 2 min prior to addition of Ac- or Asm lysis 
buffer. Samples were then homogenized in a TissueLyser for 5 Min at 50 Hz. An aliquot was 
removed for protein determination and another aliquot was dispensed on ice for determination 
of Ac- or Asm activity. Ac- or Asm lysis buffer was added to a final volume of 20 µl. Samples 
and the NBD-ceramide or BODIPY-sphingomyelin substrate solutions were sonicated in an 
ultrasonic bath for 10 min to induce micelle formation, before 100 pmol/sample NBD-ceramide 
or 100 pmol/sample BODIPY-sphingomyelin were added to the samples. The reaction was 
carried out for 2 h (Ac) or for 1 h (Asm) at 37 °C. The reaction was terminated by lipid 
extraction through addition of chloroform:methanol (2:1, v/v), vortexing and centrifugation for 
5 min at 15 000 x g. The lower phase was collected and dried in a SpeedVac at 37 °C. Dried 
lipids were resuspended in 20 µl chloroform:methanol (2:1, v/v) and spotted onto a thin layer 
chromatography (TLC) plate. The TLC run was conducted with ethyl acetate:acetic acid (100:1, 
v/v, Ac) or chloroform:methanol (80:20, v/v, Asm) as the running buffer. The plate was then 
dried and imaged using a Typhoon FLA 9500. Spots were quantified with ImageQuant 
software.  
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3.2.2.3 Ceramide and sphingomyelin quantification 
Ceramides and sphingomyelins were quantified by Dr. Fabian Schumacher (University 
Duisburg-Essen und University Potsdam) by rapid resolution liquid chromatography/mass 
spectrometry as recently described (Huston et al. 2016): Lipids were extracted from spleen 
tissues with C17-ceramide and C16-d31-sphingomyelin as internal standards. Sample analysis 
was conducted by rapid-resolution liquid chromatography-MS/MS using a Q-TOF 6530 mass 
spectrometer operating in the positive ESI mode. Ceramide precursor ions (C16-ceramide 
(m/z 520.508), C17-ceramide (m/z 534.524), C18-ceramide (m/z 548.540), C20-ceramide 
(m/z 576.571), C22-ceramide (m/z 604.602), C24-ceramide (m/z 632.634) and C24:1-ceramide 
(m/z 630.618)) were cleaved into the fragment ion m/z 264.270 and sphingomyelin precursor 
ions (C16-sphingomyelin (m/z 703.575), C16-d31-sphingomyelin (m/z 734.762), C18-
sphingomyelin (m/z 731.606), C20-sphingomyelin (m/z 759.638), C22-sphingomyelin 
(m/z 787.669), C24-sphingomyelin (m/z 815.700) and C24:1-sphingomyelin (m/z 813.684)) 
were cleaved into the fragment ion m/z 184.074. Quantification was performed with 
MassHunter Software. 
 
3.2.2.4 Histopathological assessment 
Mice were sacrificed by CO2 exposure and perfused with 0.9 % sodium chloride via the right 
ventricle to remove red blood cells, followed by perfusion with 4 % PFA. Organs were dissected 
and fixed further in 4 % PFA, de-calcified with Decalcifier soft (Roth) if necessary, dehydrated 
with ethanol, embedded in paraffin and trimmed to 6 µm thin sections. These were stained with 
hematoxylin and eosin, Masson trichrome staining kit or SafraninO/FastGreen as indicated. 
Samples were analyzed on a Leica SP5. 
 
3.2.2.5 Blood, serum and urine analysis 
Blood was drawn from the tail vein and serum was collected by centrifugation as previously 
described (please refer to section 3.2.1.4). Insulin levels were quantified by enzyme-linked 
immunosorbent assay (ELISA) and creatinine levels using a colorimetric assay kit according to 
the respective manufacturer’s instructions. All other serum parameters were analyzed using a 
SpotChem EZ chemistry analyzer and the corresponding parameter strips from Scil. When 
necessary, samples were diluted in Aqua dest to enable measurement of small sample volumes 
or to obtain an accurate measurement when sample contents exceeded the maximum  
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detection limit of a given parameter. The differential blood count was obtained from EDTA-
anti-coagulated full blood using a VetABC.  
Urine was caught into a collection tube when mice urinated prompted by removal from their 
cages. Levels of ß-hydroxybutyrate and glucose were quantified using colorimetric assay kits 
(Cayman) and protein levels by Bradford protein assay.  
 
3.2.2.6 MCP-1 quantification 
Monocyte chemoattractant protein-1 (MCP-1) levels were measured by enzyme-linked 
immunosorbent assay. Mice were sacrificed by CO2 exposure, blood was drawn from the 
V. cava inferior and serum was obtained by centrifugation at 2,500 x g for 20 min. The spleen, 
liver and brain were dissected, snap-frozen and homogenized in PBS + 10 µg/ml Aprotinin + 
10 µg/ml Leupeptin + 1 x Complete Protease Inhibitor Cocktail using a TissueLyser as 
described above (please refer to section 3.2.1.7). Samples were centrifuged for 5 min at 
15 000 x g to remove debris and MCP-1 levels were analyzed using the R&D Quantikine 
ELISA according to manufacturer’s instructions. Serum samples were directly analyzed 
without any further treatment.  
 
3.2.2.7 Joint cytokine measurements 
Arthritis was induced as described in section 3.2.1.3 and mice were sacrificed on day 2 or on 
day 4 after arthritis induction as indicated. Joint homogenates were prepared as described by 
Rioja and colleagues with slight alterations (Rioja et al. 2004): Whole knee joints (synovium, 
adjacent tissues and bone) were removed, snap-frozen and pulverized using a mortar and pestle 
under liquid nitrogen. The organ powder was transferred to pre-cooled 15 mL reaction tubes on 
dry ice. Samples were resuspended in 1 mL cold PBS containing 10 µg/ml each of Aprotinin 
and Leupeptin and 1 x Complete Protease Inhibitor Cocktail. Samples were vortexed, spun 
down at 300 x g for 5 Min at 4 °C and then sonicated three times for 10 sec each. Homogenates 
were centrifuged at 400 x g for 10 Min at 4 °C. The supernatants were transferred to 1.5 mL 
tubes and centrifuged again at 15,000 x g to remove insoluble components. The supernatants 
were collected, protein content was quantified by Bradford protein assay and cytokine levels 
were assessed using R&D Quantikine ELISA kits according to the manufacturer’s instructions. 
For IL-1ß and IL-6 analyses, samples were routinely  
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diluted with the respective calibrator diluent to prevent samples from exceeding the linear range 
of the respective ELISA.  
3.2.2.8 Analysis of lymphocyte subsets 
Immunized mice were sacrificed on experimental day 0 (21 days after the initial immunization) 
and inguinal lymph nodes were resected. Single cell suspensions were prepared by carefully 
pushing cells through a 70 µm filter. Follicular B cells were stained using labelled antibodies 
against B220, CD95, GL7, IgM and IgG. T cell subsets were stained using anti-CD4, anti-CD8, 
anti-TCRb, anti-CD62L and anti-CD44 labelled antibodies. Cells were analyzed by flow 
cytometry using a BD LSR II. Regulatory T cells were stained using the Mouse Regulatory T 
Cell Staining Kit # 1 (Affymetrix) according to the manufacturer’s instructions and analyzed 
on a BD FACS Calibur.  
 
3.2.2.9 In vitro antigen-restimulation of lymphocytes 
Immunized mice were sacrificed on experimental day 0 (21 days after the initial immunization) 
and single cell lymphocyte suspensions were prepared as described above. Cells were seeded 
at 5 x 106 cells/ml in 96-well plates in serum-free RPMI K10. Stimulation media were added at 
a ratio of 1:1 (v/v) to achieve a final concentration of 5 % Asm-free mouse serum and 0.5 % 
Glucose in all samples. Asm-free mouse serum was obtained by drawing blood via tail vein 
incision from Asm-KO mice and subsequent centrifugation at 2 500 x g for 20 Min. When 
indicated, stimulation media also contained a final concentration of either 1 or 2 mg/ml mBSA 
or 10 µg/ml PHA-P (Sigma) and 10 U/ml mouse recombinant IL-2 (eBioscience). Cell 
proliferation was assessed after 48 h using the BrdU Cell Proliferation ELISA (colorimetric) 
kit (Roche) according to the manufacturer’s instructions. The BrdU labeling reagent was added 
for the final 24 h of incubation. The supernatants from these cultures were collected and the 
levels of IL-2, IL-4, IL-6, IL-10 and IL-17 were assessed using R&D Quantikine ELISA kits 
according to the manufacturer’s instructions.  
 
3.2.2.10 ß1-Integrin activation 
Blood was drawn from healthy volunteers into NH4-Heparin collection tubes. PBMCs were 
isolated by Ficoll gradient centrifugation. Cells were then washed and allowed to rest for 8 Min 
at 37 °C. Subsequently, anti-human ß1-Integrin-ß1 antibody (Merck Millipore, clone HUTS4) 
was added to a final concentration of 1 µg/sample and cells were stimulated with  
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either 1mM Mn2+ or 2 U/ml bacterial sphingomyelinase (bSM) for 10 Min at 37 °C. The ß1-
Integrin staining was continued for 20 min on ice after the stimulation, cells were then washed 
and incubated with the respective, labelled secondary antibody (Alexa Fluor 488 goat anti-
mouse; Jackson Immuno) and analyzed by flow cytometry on a BD FACS Calibur. 
 
3.2.2.11 Statistical analyses 
Data are presented as arithmetic mean ± standard deviation. For multiple comparisons, normal 
distribution of data was first confirmed with D’Agostino & Pearson omnibus normality test. 
Analysis of variance (ANOVA) was then employed with Bonferroni posttests to assess 
significant differences between selected pairs. Ordinal data (histopathological scores) were 
compared using the non-parametric Wilcoxon-signed rank test. Survival curves were compared 
using log-rank/Mantel-Cox test.  
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4. Results 
4.1 Asm inhibition for the treatment of FD  
4.1.1 Molecular characterization of the Asah1 knock-out mouse 
4.1.1.1 Knock-out strategy 
A conditional Asah1 knock-out model was generated through flanking Exon1 with loxP sites 
and removal of the neomycin selection cassette via crossing to Flp recombinase deleter mice. 
To generate the constitutive knock-out model, the floxed mice were mated with EIIa-cre deleter 
mice and heterozygous mice were subsequently mated among each other.  
 
Figure 8: Knock-out strategy – (A) The structure of the murine Asah1 gene in the Asah1fl/fl EIIa-cretg 
constitutive knock-out line is schematically shown. LoxP sites were added flanking Exon 1. Upon EIIa-cre 
mediated excision, Exon1 is thus deleted in the Asah1-/- mice. Image adapted from (Moser 2001). (B) The 
beginning of the Asah1 mRNA sequence is shown (NCBI Reference Sequence: NM_019734.2) in open-reading 
frame. The sequences encoding the signal peptide and the α-unit are highlighted in color. Grey boxes indicate 
potential alternative start codons, an additional black frame indicates that these fit the open reading frame. 
Underlined codons are putative non-ATG start codons.  
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Figure 8A schematically shows the target genotypes resulting from heterozygous mating after 
crossing to EIIa-Cre mice. Exon1 includes the sequence for the start codon to initiate 
translation. Figure 8B shows part of the Asah1 mRNA sequence in open-reading frame. Several 
potential alternative start codons are highlighted (grey boxes), as well as some putative non-
ATG start codons (underlined). Some of these fit the open-reading-frame (black frame). 
However, no alternative start sequence is present in front of the signal peptide. It has not been 
investigated which of the potential alternative start codons is used in our model.  
 
4.1.1.2 Knock-out of Ac signal peptide disrupts lysosomal targeting 
Since knock-out of Exon1 deletes the signal peptide sequence, the protein expressed in  
Asah1-/- mice should display disrupted lysosomal targeting. Intracellular localization of Ac was 
therefore assessed by confocal microscopy in mesenchymal stem cells isolated from either Wt- 
or Ac-deficient mice. Cells were stained with an anti-Ac antibody in parallel with an antibody 
directed against the lysosomal marker protein LAMP1 to visualize the lysosomes and determine 
colocalization.  
 
Figure 9: Deletion of acid ceramidase-signal peptide disrupts lysosomal targeting – Immunofluorescence 
staining of mesenchymal stem cells with antibodies directed against Acid ceramidase (Ac, red) and the 
lysosomal marker LAMP1 (green). Scale bar: 10 µm. Representative images are shown.  
Immunofluorescence analysis showed colocalization of Ac with the lysosomal marker in Wt 
cells (Fig. 9). No such colocalization was observed in the Ac-deficient cells. Instead, Ac-
staining in the Asah1-/- cells followed a diffuse, cytosolic pattern. 
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4.1.1.3 Reduction of Ac activity in Asah1 knock-out mice 
To assess the effect of the KO-model on Ac activity, an enzyme activity assay using NBD-
labeled ceramide as a substrate was established. Organs were lysed, micelles were induced by 
sonication, the labelled ceramide substrate was added and incubated at 37 °C. The reaction was 
terminated by lipid extraction and the non-deacetylated substrate was separated from the 
liberated fatty acid through TLC. Spots were scanned with a Typoon FLA 9500 and quantified 
using ImageQuant software. The linearity of the assay was confirmed for each organ in the 
respective protein range by control reactions (data not shown).  
 
Figure 10: Acid ceramidase activity & ceramide accumulation – Assessment of acid ceramidase (Ac) 
activity upon knock-out of the signal peptide. Organ lysates were prepared and incubated in the presence of 
NBD-labeled ceramide. Means ± SD from n = 4-7 mice are depicted. Data passed the D’Agostino & Pearson 
omnibus normality test. Asterisks indicate significant differences as assessed by 2-way ANOVA with 
Bonferroni posttests: * p < 0.05; ** p < 0.01; *** p < 0.001.   
Ac activity is reduced in Ac-KO mice in a tissue-specific manner (Fig. 10). Significant 
reduction in activity was observed for most of the lymphoid organs with the lymph nodes as 
the sole exception. Ac activity was also significantly reduced in the liver. Residual activity was 
present in all tested organs.  
 
4.1.2 Pathological assessment of FD manifestations and effect of Asm ablation 
4.1.2.1 Ceramide accumulation in Ac-deficient mice is blunted by Asm-deficiency 
To assess if ASM inhibition would be therapeutically beneficial for FD, a preliminary rescue 
study was conducted in mice by crossing the Ac-deficient line to an Asm-deficient line. 
Ceramide and sphingomyelin levels were assessed by mass spectrometry.  
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Figure 11: Ceramide and sphingomyelin quantification – The effect of acid ceramidase and acid 
sphingomyelinase knock-out on ceramide (A) and sphingomyelin (B) levels were analyzed by rapid resolution 
liquid chromatography/mass spectrometry of homogenates of snap-frozen spleen samples. Means ± SD from 
n = 5 mice are depicted. Data passed the D’Agostino & Pearson omnibus normality test. Asterisks indicate 
significant differences as assessed by ANOVA with Bonferroni posttests (* p < 0.05; ** p < 0.01; 
*** p < 0.001). No significant differences were detected for C18-, C20-, C22- and C24-ceramides and 
sphingomyelins.  
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Total ceramide was approximately 130-fold elevated compared to Wt mice upon Ac-deficiency. 
All individual ceramide species were also elevated irrespective of chain length, but only the 
increase in C16- and C24:1 ceramide was statistically significant (Fig. 11A). Total 
sphingomyelin and C16-sphingomyelin levels also increased upon Ac-deficiency, but not 
significantly. Crossing of Ac-deficient mice to Asm-deficient mice blunted ceramide 
accumulation in FD mice both in heterozygous and homozygous Smpd1 mice. Whereas C16- 
and C24:1-ceramides were normalized, total ceramide levels were still significantly higher than 
in Wt mice. On the other hand, the double mutants had comparable sphingomyelin levels to 
Asm-mono-deficient mice, but the increase in total sphingomyelin was blunted.  
 
4.1.2.2 Body weight and survival 
To analyze the biological effects of reduced Ac activity and ceramide accumulation and the 
therapeutic relevance of the partially reduced ceramide levels in Asah1-/- / Smpd1-/- double 
mutants, mice were monitored with regard to their body weight and survival.  
 
 
Figure 12: Body weight and survival of Asah1-/- and Asah1-/- / Smpd1-/- double-deficient mice - (A) Body 
weight of different genotypes. Mice were weighted once a week starting after weaning. Given are means ± SD 
from n = 3-33 mice per group and time-point. Data passed the D’Agostino & Pearson omnibus normality test 
and were compared by ANOVA with Bonferroni posttests. Asterisks indicate significant differences to Wt 
mice: ** p < 0.01; *** p < 0.001  
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Figure 12 (continued): Body weight and survival of Asah1-/- and Asah1-/- / Smpd1-/- double-deficient mice 
- (B) Survival curve of different genotypes. Mice were monitored daily. Survival of n = 7-25 mice was 
compared using log-rank (Mantel-Cox) test. Dark grey asterisks indicate significant differences to Wt mice, 
light grey asterisks indicate significant differences to Asah1-/- mice. *** p < 0.001. 
 
Ac-deficient mice already weight significantly less than their Wt littermates at weaning. After 
weaning, they barely gained weight and body weight started to decline at 5-6 weeks (Fig. 12A). 
Survival was markedly shortened in the Asah1-/- group: The earliest death occurred on day 41 
and no Ac-deficient mouse survived for more than 64 days. The mean survival time was 51 
days. No Wt mice died during the entire observation period (Fig. 12B).  
Asah1-/- / Smpd1-/- double-deficient mice appeared to develop normally until 13 weeks of age, 
when body weight slowly started to decline (Fig. 12A). Survival of Ac-KO mice was markedly 
enhanced by Asm-deficiency: The average survival time of the double knock-out mice was 151 
days and thus approximately 3 times longer than that of regular Ac-deficient mice (Fig. 12B). 
Heterozygous depletion of Smpd1 was less beneficial – both in terms of weight gain and 
survival (Fig12. A+B) and failed to yield statistically relevant differences.   
 
4.1.2.3 Histiocytic infiltration in lymphoid tissues 
A key feature of FD is granuloma formation. To investigate if any such changes are present in 
the Asah1-KO model and possibly ameliorated by Asm co-ablation, a histopathological analysis 
was conducted on perfused, PFA-fixed and paraffin-embedded tissue samples. Additionally, 
MCP-1 levels were quantified by ELISA in the spleen and serum, because a recent cytokine 
profile of FD patients has suggested MCP-1 to be the driver of macrophage  
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infiltration and further inflammatory cytokine production in FD (Alayoubi et al. 2013; Dworski 
et al. 2017) 
 
Figure 13: Histiocytic infiltration in lymphoid tissues – (A) HE staining of perfused, PFA-fixed and paraffin-
embedded tissue sections. Scale bar: 50 µm. Representative images are shown. (B+C) Histiocytic  
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infiltration with foamy macrophages were exemplary scored on a scale of 0 (no signs) to 4 (very severe) in 
spleen (B) and thymus (C) by a blinded investigator. Graphs depict each replicate and the mean ± SD. Indicated 
p-values are the result of Wilcoxon signed-rank test. 
 
Figure 13 (continued): Histiocytic infiltration in lymphoid tissues – (D-E) MCP-1 levels in spleen (D) and 
serum (E) were quantified by ELISA. Given are means ± SD of n = 5-12 mice per group. Data passed the 
D’Agostino & Pearson omnibus normality test. Asterisks indicate significant differences as assessed by 
ANOVA with Bonferroni posttests: *** p < 0.001.   
Ac-deficient mice showed massive histiocytic infiltrations in all lymphoid tissues with a 
concomitant disturbance of the underlying tissue architecture (Fig. 13A). The infiltrates have 
the appearance of foamy macrophages and were confirmed as such by a pathologist (PD Dr. 
Jan Becker, University Hospital Cologne, personal communication). Foamy macrophages were 
also present in the gut associated lymphoid tissues (not shown).  
Heterozygous depletion of Asm in Ac-deficient mice reduced histiocytic infiltration in a subset 
of mice in the thymus and spleen (Fig13. A-C). Complete genetic ablation of Asm in Ac-
deficient mice had even better and more uniform outcomes: Reduction of histiocytic infiltrates 
were seen in all lymphoid tissues and in all mice except for one (Fig. 13A-C). Histiocytic 
infiltration was also reduced in the lymph nodes (Fig. 13A).  
MCP-1 quantification showed elevated levels of this chemokine in the spleen (Fig. 13D) and 
serum (Fig. 13E) upon Asah1 knock-out. Both heterozygous and homozygous co-deficiency of 
Asm blunted the MCP-1 elevation in FD mice significantly (Fig. 13D-E).  
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4.1.2.4 Joint pathology 
Joint manifestations are one of the key features of FD. To investigate if the Asah1 knock-out 
model mimics this feature of the disease, knee joints were dissected and analyzed histologically.  
 
Figure 14: Synovial hyperplasia in knee joints – SafraninO/FastGreen staining of PFA-fixed, de-calcified 
and paraffin-embedded knee joint sections. Representative images from 5 mice per group are shown.   
Knee joints of Ac-deficient mice exhibited pronounced synovial hyperplasia. The hyperplastic 
tissue appeared to consist mostly of cells with the same foamy-macrophage-like appearance  
 
Results 
 
59 
 
as the histiocytic infiltrates in the lymphoid tissues. No pannus formation, cartilage loss or bone 
erosions were observed, as well as no other signs of inflammation including no exudation into 
the joint cavity (Fig. 14). Synovial hyperplasia was partially reduced upon Asm co-deficiency.   
 
4.1.2.5 Lung inflammation 
Pulmonary involvement has been reported for all severely affected FD patients. The lungs of 
Asah1-KO mice therefore were also evaluated histologically.  
 
Figure 15: Increased cell numbers in acid ceramidase deficient lungs – (A) HE staining of perfused, PFA-
fixed and paraffin-embedded lung sections. Scale bar: 50 µm. Representative images are shown. (B) Lung 
infiltration was scored on a scale of 0 (no signs) to 4 (very severe) by a blinded investigator. Graphs depict each 
replicate and the mean ± SD. Indicated p-values are the result of Wilcoxon signed-rank test of the respective 
genotype compared to Asah1-/- mice.  
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Ac-deficient mice showed an increased number of cells in the lung, including foamy 
macrophages. Additionally, there was also an increased number of smaller cells, which have 
the appearance of neutrophils (Fig. 15).  
The lung phenotype of Ac-deficient mice was also analyzed further and compared to the CF 
phenotype, since ceramide accumulation was also reported in CF lungs. Since these further 
studies constitute an independent project and were conducted in co-operation with a 
postdoctoral fellow at our institute, they are not included in this thesis. Briefly, we confirmed 
the significant increase of total cell number/lung in Asah1-/- mice by flow cytometry. Whereas 
dendritic cells were significantly decreased upon Ac-deficiency, neutrophils were significantly 
increased. Preliminary data also shows an increase in macrophages, myeloid-derived 
suppressor cells and CD4+ CD8+ double positive T cells, whereas all other T cell subsets were 
unaltered or reduced. Preliminary cytokine analysis also shows showed an increase in various 
cytokines, including for instance MCP-1 and IL-8 (Beckmann & Kadow, unpublished data).  
The lungs of Asah1-/- / Smpd1-/- double mutant mice show a slight, but not significant tendency 
toward more macrophage infiltration (Fig. 15A), which matches the reported lung phenotype 
of Smpd1 knock-out mice (Kuemmel et al. 1997).  
 
4.1.2.6 Liver pathology 
Hepatic involvement has been reported for the more severe forms of FD and up to 25 % of FD 
patients exhibit liver failure (Bao et al. 2017). An initial insight into liver manifestations of FD 
in the Asah1-KO mice and potential amelioration by Asm-deficiency was therefore obtained by 
histology.  
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Figure 16: Liver histopathology – (A) HE and Masson Trichrome staining of perfused, PFA-fixed and 
paraffin-embedded liver sections. Scale bar: 50 µm. 4-6 mice were analyzed per group. Representative images 
are shown. (B-C) Macrophage infiltration (B) and liver fibrosis (C) were scored on a scale of 0 (no signs) to 4 
(very severe) by a hepato-pathologist. The graphs depict each replicate and the mean ± SD. Indicated p-values 
were determined by Wilcoxon-signed rank test.  
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Analysis of the liver revealed conspicuous patches in Asah1-KO mice, which were mostly 
located around the central veins. These were subsequently confirmed to be fibrous by Masson-
Trichrome staining and staged by a blinded pathologist (Jiang Wang, MD, PhD, University of 
Cincinnati, personal communication) as early stages of pericentral and pericellular hepatic 
fibrosis (Fig. 16A+C). Some foamy macrophages were also present - both within the fibrotic 
areas and isolated outside of them (Fig. 16A+B). Whereas macrophage infiltration in the liver 
was not significantly affected by Asm-depletion (Fig. 16A+B), liver fibrosis was almost 
completely absent (Fig16. A+C). 
Given these findings, a more detailed analysis of liver function was conducted. Clinical liver 
parameters were assessed in the serum using a dry chemistry system (Scil SpotchemTM).  
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Figure 17: Serum analysis of liver parameters – (A-F) Liver parameters were analyzed in serum using a Scil 
SpotchemTM. Graphs depict the mean ± SD of n = 6-11 mice per group. Data passed the D’Agostino & Pearson 
omnibus normality test and asterisks indicate multiplicity adjusted p-values as determined by ANOVA with 
Bonferroni posttests: * p < 0.05; ** p < 0.01; *** p < 0.001. ♯ indicates significant differences compared to the 
age matched Wt group, * to the age-matched Asah1-/- group and + the comparison of the different ages within 
the given genotype or the comparison of Smpd1-/- with Asah1-/- / Smpd1-/- double  
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deficient mice respectively. No significant differences were detected for total protein (A) and total bilirubin 
(C).  
Whereas total serum protein, albumin and total bilirubin (Fig. 17A-C) were not altered, liver 
transaminases and LDH were significantly increased (Fig. 17D-F) in Ac-deficient mice. We 
also analyzed Gamma-glutamyl-transferase, but all samples were below the detection limit 
(data not shown). Hepatic damage worsened with age, but could be improved significantly 
already by heterozygous depletion of Asm, and even more so by homozygous depletion of Asm 
(Fig. 17 D-F).  
 
4.1.2.7 Hematological manifestations  
Hematological manifestations of FD were indicated in some case reports (Antonarakis et al. 
1984; Fujiwaki et al. 1992; Mondal et al. 2009), but have not been reported with any clear 
consistency. To gain further insights, blood counts were prepared.  
Results 
 
65 
 
 
Figure 18: Blood count – Blood counts were obtained using Scil VetABCTM. Given are means ± SD of n = 5-
17 mice per group. Data passed the D’Agostino & Pearson omnibus normality test and asterisks indicate 
multiplicity adjusted p-values as determined by ANOVA with Bonferroni posttests: * p < 0.05; ** p < 0.01; 
*** p < 0.001. ♯ indicates significant differences compared to the age matched Wt group, * to the age-matched 
Asah1-/- group and x the comparison of Smpd1-/-  with Asah1-/- / Smpd1-/- double deficient mice. No significant 
differences were detected for hematocrit (H).  
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Ac-deficient mice showed significantly decreased white blood cell counts (Fig. 18A), whereas 
the red blood cell count (Fig. 18B) was slightly increased. Ac-deficient erythrocytes had 
reduced mean corpuscular hemoglobin (Fig. 18G), but the total amount of hemoglobin was not 
changed (Fig. 18C). Other erythrocyte indices and hematocrit were normal (Fig. 18D, F, H). 
Platelet number was reduced, albeit not significantly (Fig. 18E). Heterozygous depletion of 
Asm showed no or only mild improvements, whereas homozygous knock-out of Smpd1 
normalized all parameters (Fig. 18A-G).  
 
4.1.2.8 Muscular manifestations 
Creatinine phosphokinase (CPK) indicates damage of tissues that rapidly consume ATP (i.e. 
muscle tissue, brain) and is thus used as a marker for myocardial infarction, rhabdomyolysis, 
muscular dystrophy, acute kidney injury and some other conditions. It was included in the test 
panel because Ac-deficient mice showed some indicators of muscular dystrophy upon 
observation (progressive wasting, scoliosis, waddling gate). Additionally, mutations in the 
ASAH1 gene have been reported in a subset of spinal muscular atrophy patients (Dyment et al. 
2014; Filosto et al. 2016; Gan et al. 2015; Zhou et al. 2012) and some patients have even been 
reported to suffer from both FD and spinal muscular atrophy (Teoh et al. 2016). Elevated CPK 
activity is frequently reported in spinal muscular atrophy patients (Rudnik-Schoneborn et al. 
1998).  
 
Figure 19: Creatinine phosphokinase quantification – Creatinine phosphokinase levels were quantified in 
serum using a Scil SpotchemTM. Given are means ± SD from n = 5-10 mice per group. Data passed the 
D’Agostino & Pearson omnibus normality test and asterisks indicate multiplicity adjusted p-values as 
determined by ANOVA with Bonferroni posttests: * p < 0.05; ** p < 0.01; *** p < 0.001. ♯ indicates 
significant differences compared to the age matched Wt group, * to the age-matched Asah1-/- group and + the 
comparison of the different ages within the given genotype or the comparison of Smpd1-/- with Asah1-/- /  
Smpd1-/- double deficient mice respectively. 
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CPK levels were significantly elevated even in young Ac-deficient mice and increased further 
with age (Fig. 19). Co-deficiency of Asm significantly blunted CK elevation and even 
normalized them upon complete Asm depletion (Fig. 19).  
 
4.1.2.9 Metabolism 
The reduced body weight and size of Ac-deficient mice prompted an investigation into their 
metabolism. We analyzed glucose levels in the serum, as well as the ketone body ß-
hydroxybutyrate in the urine. Ketonuria occurs when alternative sources of energy are being 
used, e.g. during starvation or in type I diabetes mellitus.  
 
Figure 20: Metabolic analysis – (A) Serum analysis of glucose levels of n = 6-11 mice per group. (B) Levels 
of ß-hydroxybutyrate were quantified in urine of n = 7-14 mice per group using a colorimetric assay. (A-B) 
Given are means ± SD. Data passed the D’Agostino & Pearson omnibus normality test and was subsequently 
compared by ANOVA with Bonferroni posttests: * p < 0.05; ** p < 0.01; *** p < 0.001. (A) ♯ indicates 
significant differences compared to the age matched Wt group, * to the age-matched Ac-KO group and + the 
comparison of the different ages within the given genotype. 
 
Serum glucose levels were decreased in Ac-deficient mice and declined progressively. 
Hypoglycemia reached statistical significance in the older Ac-deficient mice (Fig. 20A). 
Heterozygous depletion of Asm did not sufficiently improve glucose levels (Fig. 20A). 
Complete depletion of Asm in Asah1-/- mice ameliorated hypoglycemia significantly, but could 
not restore it to Wt levels (Fig. 20A). Given the observed hypoglycemia, insulin levels were 
also analyzed. However, insulin levels remained below the detection limit of the assay in almost 
all samples (not shown).  
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Ketonuria was also assessed. The levels of the ketone body ß-hydroxybutyrate in the urine were 
slightly decreased in Ac-deficient mice, but not significantly when compared to Wt littermates 
(Fig. 20B).  
 
4.1.2.10 Kidneys 
Although kidneys have high AC expression (Li et al. 1999) and ceramide was reported to 
accumulate in the kidneys of FD patients as well (Fujiwaki et al. 1995), little is known about 
FD manifestations in the kidney. Renal FD manifestations were therefore investigated by 
histological analysis and by determination of different functional kidney parameters.  
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Figure 21: Analysis of kidney function – (A) HE staining of perfused, PFA-fixed and paraffin-embedded 
kidney sections. Scale bar: 50 µm. Representative images of n = 4-6 mice per group are shown. (B-E) Blood 
urea nitrogen (B), urinary protein (C) and urinary glucose (D) were quantified.  Given are means ± SD of n = 6-
15 mice per group. Data passed the D’Agostino & Pearson omnibus normality test and was subsequently 
compared by ANOVA with Bonferroni posttests: * p < 0.05; ** p < 0.01; *** p < 0.001.  ♯ indicates significant 
differences compared to the age matched Wt group, * to the age-matched Ac-KO group and + the comparison 
of the different ages within the given genotype. 
Histologic analysis showed no pathologies in the kidney upon Ac-deficiency (Fig. 21A). A 
seasoned nephrotic pathologist confirmed this finding (PD Dr. Jan Becker, University Hospital 
Cologne, personal communication). However, blood urea nitrogen (BUN) levels  
Results 
 
70 
 
were significantly increased in Ac-deficient mice above 5 weeks of age (Fig. 21B). Additional 
markers of kidney function and damage were therefore assessed only in the older mice. Serum 
creatinine remained below the detection limit of 0.2 mg/dl (not shown). Urinary protein levels 
decreased in Ac-deficient mice (Fig. 21C) and a significant loss of glucose via the urine was 
detected (Fig. 21D). Homozygous depletion of Asm normalized all parameters, whereas 
heterozygous depletion of Asm did not improve urinary protein and glucose excretion.  
 
4.1.3 Pharmacological inhibition of Asm in Asah1 knock-out mice  
4.1.3.1 Treatment of juvenile Asah1 knock-out mice with Amitriptyline 
Given the beneficial effects of genetic Asm-depletion on FD manifestations and survival, Asm 
was targeted pharmacologically with the functional Asm inhibitor Amitriptyline to translate the 
findings to a setting with clinical applicability. In a first study, Ac-deficient mice were treated 
with Amitriptyline via the drinking water from week 4 onwards and survival was monitored.  
 
Figure 22: Survival of juvenile acid ceramidase deficient mice upon Amitriptyline treatment – Asah1-/- 
mice received 180 mg/L Amitriptyline hydrochloride (AMI) in 0.9 % saline solution as their drinking water 
with ad libitum access or only saline solution (NaCl). Treatment commenced 4 weeks after birth. Survival was 
monitored by daily visitation. Indicated p-values are the result of log-rank (Mantel-Cox) test: Light gray 
indicates the comparison between Amitriptyline and placebo-treated Asah1-/- mice and dark grey the 
comparison between Amitriptyline treated groups.  
Treatment with Amitriptyline severely shortened the survival time of Asah1-/- mice compared 
to their untreated counterparts. Death typically occurred within days of treatment and the 
median survival time was only 37 days. Amitriptyline treatment had no adverse effects on age-
matched Wt mice – all Wt mice survived for the entire observation period and showed no signs 
of health impairment (Fig. 22).  
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4.1.3.2 Amitriptyline treatment throughout development 
4.1.3.2.1 Survival upon Amitriptyline treatment 
Given the apparent contrast of prolonged survival of Asah1-/- mice upon genetic co-ablation of 
Smpd1 and shortened survival upon pharmacological Asm inhibition, a second pharmacological 
study with Amitriptyline was employed. In the second study, Amitriptyline treatment was 
already started in utero through treatment of the Asah1+/- mothers. After birth, treatment of the 
offspring was continued through breast milk via treatment of the mothers until the offspring 
was weaned. Then, treatment of the juvenile mice was continued directly via the drinking water. 
The aim of the second study was to commence Amitriptyline early enough to prevent significant 
ceramide accumulation. Survival of treated mice was monitored daily.  
 
Figure 23: Survival upon Amitriptyline treatment throughout development – Asah1-heterozygous mice 
were mated for four days. Pregnant females then received either 180 mg/L Amitriptyline hydrochloride (AMI) 
in 0.9 % saline solution or only saline solution (NaCl) as their drinking water with ad libitum access. Treatment 
was continued after birth. After weaning, the offspring received Amitriptyline or placebo as drinking water in 
the same dose. Survival was monitored by daily visitation and compared using log-rank (Mantel-Cox) test. 
Amitriptyline treatment throughout development did not improve the survival of Ac-deficient 
mice. Instead, they died shortly after weaning and thus at a similar age to the mice that received 
Amitriptyline at an age of 4 weeks. No adverse effects of Amitriptyline treatment were observed 
in Wt mice and the vehicle alone also had no effect (Fig. 23).  
 
4.1.3.2.2 Asm and Ac activity upon Amitriptyline treatment 
Since no differences in survival were observed whether Asah1-/- mice were treated with 
Amitriptyline throughout development or starting from an age of 4 weeks, the efficacy  
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of Amitriptyline treatment via the mothers was assessed by with an enzyme activity assay using 
BODIPY-labeled sphingomyelin as a substrate.  
 
Figure 24: Acid sphingomyelinase activity upon Amitriptyline treatment – (A) Pregnant females received 
either 180 mg/L Amitriptyline hydrochloride (AMI) in 0.9 % saline solution, or only saline solution (NaCl) as 
their drinking water with ad libitum access. Treatment was continued after birth. After weaning, offspring was 
sacrificed and spleens were dissected. (B) Adult Wt mice were treated with either Amitriptyline or saline 
solution as described above and sacrificed after 4 weeks. Spleens were dissected. (A+B) Acid sphingomyelinase 
(Asm) activity was assessed using BODIPY-labeled sphingomyelin as a substrate. Given are means ± SD of n 
= 3-6 mice per group.   
The results show that Amitriptyline treatment via the mothers was insufficient to cause a 
reduction of Asm activity in the offspring (Fig. 24A). Direct treatment of adult Wt mice with 
the same dose, however, resulted in an almost 80 % reduction of Asm activity (Fig. 24B).  
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4.2. Asm inhibition for the treatment of RA 
4.2.1 Susceptibility of Smpd1 knock-out mice to experimental arthritis 
To define the role of ASM in RA, we utilized a murine antigen-induced arthritis model that 
mimics some features of the human disease. Asm-deficient mice and wild-type littermates were 
compared in this model. Joint swelling and joint histopathology were assessed during the acute 
phase of inflammation.  
 
Figure 25: Acid sphingomyelinase-deficiency ameliorates experimental arthritis severity – (A+B) AIA 
was induced in Smpd1-/- mice and Wt littermates. (A) Joint swelling was monitored over 5 days by measuring 
joint diameter with a digital caliper. Data are presented as the ratio of the arthritic joint to the vehicle-injected 
control joint as mean ± SD of n = 9-11 mice per group. Data passed the D’Agostino & Pearson omnibus 
normality test and was subsequently compared by repeated measures 2-way ANOVA with Bonferroni posttests: 
** p < 0.01; *** p < 0.001.  (B) On day 4 after arthritis induction, knee joints were dissected and Masson-
Goldner stained sections were prepared. Representative images of n = 4-5 mice per group are shown. Scale bar: 
1 mm.  
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Joint swelling was monitored over a period of 5 days and was markedly reduced upon Asm-
deficiency (Fig. 25A). On experimental day 4 after arthritis induction, joints were dissected and 
analyzed histologically. Asm-deficient mice showed reduced histopathological signs of arthritis 
(Fig. 28B). 
Given the observed differences, the severity of arthritis in Smpd1-/- mice was analyzed further 
by quantification of articular pro- and anti-inflammatory cytokine levels with commercially 
available ELISA kits.  
 
Figure 26: Reduced levels of articular pro-inflammatory cytokines upon Smpd1 kock-out – (A-C) AIA 
was induced and on day 4 (A-C) after arthritis induction knee joints were dissected and levels of IL-1ß (A), IL-
6 (B), IL-17 (C) were quantified by ELISA. Data are presented as the amount of the respective cytokine per 
mg protein ± SD of n = 9-10 mice per group. Data passed the D’Agostino & Pearson omnibus normality test 
and asterisks indicate significant differences as assessed by 2-way ANOVA with Bonferroni posttests: 
*** p < 0.001. 
Concurrently to the histological reduction of arthritis severity, levels of the pro-inflammatory 
cytokines IL-1ß, IL-6 and IL-17, which mark synovial inflammation, were also significantly 
reduced in the arthritic joint of Smpd1-/- mice (Fig. 26A-C).  
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4.2.2 B- and T-Cell numbers and in vitro responses upon immunization are unaffected 
by Asm-deficiency 
Reduced arthritis severity in Smpd1-/- mice could potentially result from an insufficient response 
to the immunization. Different lymphocyte subsets were analyzed in immunized mice to assess 
the efficacy of immunization in Asm-deficient mice.  
 
Figure 27: Smpd1 knock-out has no effect on B- and T-Cell numbers after immunization – (A-D) Mice 
were immunized with mBSA and lymphocytes were isolated from inguinal lymph nodes on experimental day 
0. Different lymphocyte subsets were analyzed by flow cytometry. Data are presented as the mean of the 
absolute cell numbers per lymph node of n = 4-8 mice ± SD. Significant differences were assessed by 2-way 
ANOVA with Bonferroni posttests, but no significant differences were detected. T-helper (A) and cytotoxic T-
Cells (B) cells: Naiv: TCRbeta+, CD62L+, CD44-; central memory: TCRbeta+, CD62L+, CD44+; effector 
memory: TCRb+, CD62L-, CD44+. Regulatory T-Cells (C): CD4+, FoxP3+; activated regulatory T-Cells: CD4+, 
FoxP3+, CD25+. B cells (D): B220+, follicular (FO) B cells: B220+, CD95+, Gl7+; class-switched (IgM→IgG) 
B cells: IgM-, IgG+.  
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No differences in T helper (Fig. 27A) or T effector cell subsets (Fig. 27B) were detected in 
Smpd1-/- mice, including no differences in the number or activation status of regulatory T cells 
(Fig. 27C). Additionally, there was also no difference in the number of B cells, including 
follicular B cells, with a similar percentage of IgM→IgG class-switched cells (Fig. 27D). 
Additionally, lymphocytes from immunized mice were isolated and re-stimulated with the 
mBSA-antigen in vitro to monitor the functional capacity of Asm-deficient lymphocytes to 
respond to antigen re-stimulation. 
 
Figure 28: Functional B- and T-Cell responses to immunization are unaffected by Smpd1 knock-out – 
(A-E) Mice were immunized with mBSA and lymphocytes were isolated from inguinal lymph nodes on 
experimental day 0. Lymphocyte were left untreated, re-stimulated with 1 mg/mL mBSA or stimulated with 
10 µg/mL PHA and 10 U/mL IL-2 in vitro and proliferation (A) was monitored or release of IL-2 (B), IL-4 (C), 
IL-6 (D) or IL-17 (E) was quantified by ELISA. Given are means ± SD of n = 4-8 mice per group. No significant 
differences were detected by repeated measures 2-way ANOVA with Bonferroni posttests.  
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Concurrently to the unaltered lymphocyte distribution in vivo in Asm-deficient mice, the 
proliferation of lymphocytes in response to antigen-restimulation in vitro was not affected by 
Asm-deficiency and neither was the release of pro-inflammatory cytokines, including markers 
of T Cell activation, i.e. IL-2, IL-4, IL-6 and IL-17 (Fig. 28C-F).  
 
4.2.3 Transfusion of wild-type platelets reverses protection in Asm-deficient mice 
Platelets have been attributed a significant role in autoimmune inflammation. In the context of 
tumor metastasis, our group has previously shown that platelet-derived Asm mediates tumor 
cell extravasation via P-selectin, p38 MAPK and ß1-Integrin (Becker et al. 2017; Carpinteiro 
et al. 2015; Carpinteiro et al. 2016). All of these molecules have also been implicated in RA 
(Grober et al. 1993; Han et al. 1999; Laffon et al. 1991; Schett et al. 2000; Schmitt-Sody, Metz, 
Gottschalk, et al. 2007). Thus, any upstream effect that impacts on adhesion and extravasation 
of lymphocytes into the joint would be bypassed by a direct infusion of platelets, while a direct 
defect in platelets would not reconstitute arthritis in Asm-deficient mice. To test these 
hypotheses, platelets were isolated from untreated donor mice and transfused to immunized 
recipients two hours prior to arthritis induction. Arthritis severity was subsequently assessed by 
monitoring joint swelling and quantifying the levels of pro-inflammatory cytokines in the joints.  
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Figure 29: Transfusion of wild-type platelets reversed protection in Smpd1 knock-out mice – (A-D) 
Immunized mice were transfused with either wild-type or Smpd1 knock-out platelets two hours prior to arthritis 
induction. (A) Joint swelling was monitored over 3 days by measuring joint diameter with a digital caliper. 
Data are presented as the ratio of the arthritic joint to the vehicle-injected control joint as mean ± SD of n = 18 
mice. (B-D) On day 2 after arthritis induction, knee joints were dissected and analyzed by ELISA for the levels 
of IL-1ß (B), IL-6 (C) and IL-17 (D). Data are presented as the amount of the respective cytokine per mg 
protein ± SD of n =9-11 mice after elimination of statistical outliers through Grubb’s test. Asterisks indicate 
significant differences as assessed by 2-way ANOVA with Bonferroni posttests: ** p < 0.01; *** p < 0.001. 
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Transfusion of Asm-deficient platelets to Smpd1-/- mice did not alter the previously observed 
reduction of arthritis severity. Upon transfusion of wild-type platelets to Asm-deficient 
recipients, however, the protective effect of Asm-deficiency was partially lost, as seen by 
significantly more joint swelling (Fig. 29A) and higher levels of pro-inflammatory cytokines in 
the joint (Fig.29 B-D). Except for IL-6, however, joint swelling and pro-inflammatory cytokine 
levels were not completely reconstituted, as they still differed significantly from wild-type in 
wild-type transfused controls.   
 
4.2.4 Sphingomyelinase stimulation activates ß1-Integrin 
Platelet-derived Asm was shown to regulate the adhesion of melanoma cells through clustering 
and activation of ß1-Integrin (Carpinteiro et al. 2015). To test if this is also the case in 
lymphocytes, we isolated PBMCs from healthy volunteers and stimulated them with 
commercially available bacterial sphingomyelinase in vitro to induce the formation of 
ceramide-enriched plasma membrane platforms. The stimulation was done in the presence of 
the HUTS-4 anti-ß1-Integrin antibody. This clone exclusively detects ß1-Integrin molecules in 
the active conformation. Activation of ß1-Integrin was monitored by flow cytometry.  
 
Figure 30: Sphingomyelinase-stimulation activates ß1-Integrin – PBMCs from healthy volunteers were 
isolated by Ficoll gradient centrifugation and were stimulated either with 10 mM Mn2+ or 2 U/mL bSM in the 
presence of an anti-active-ß1-Integrin antibody. Only live cells were considered for the analysis. A 
representative flow cytometrical analysis of four independent experiments is shown.  
Stimulation of human PBMCs with bacterial sphingomyelinase to induce the formation of 
ceramide-enriched platforms, resulted in activation of ß1-Integrin to a similar extend as the 
known Integrin activator Mn2+ (Fig. 30A).  
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4.2.5 Pharmacological inhibition of Asm ameliorates arthritis severity 
To test if the identified mechanism of platelet-Asm mediated joint inflammation could be 
exploited clinically, the efficacy of Amitriptyline treatment on suppressing arthritis severity in 
AIA was tested. For this, immunized mice were treated 4 times daily with either Amitriptyline 
or placebo starting two days prior to arthritis induction and continuing treatment throughout the 
arthritic phase. Arthritis severity was then assessed by joint swelling and articular levels of pro-
inflammatory cytokines.  
 
 
Figure 31: Pharmacological acid sphingomyelinase-inhibition ameliorates arthritis severity - (A-D) 
Immunized mice were treated with 9.375 mg/kg bodyweight Amitriptyline hydrochloride (AMI) i.p. every 
6 hours or received placebo (NaCl). Treatment commenced two days prior to arthritis induction and was 
continued until the mice were sacrificed. (A) Joint swelling was monitored over 3 days by measuring joint 
diameter with a digital caliper. Data are presented as the ratio of the arthritic joint to the vehicle-injected control 
joint as mean ± SEM of n = 9-11 mice. Asterisks indicate significant differences as assessed by 2-way ANOVA 
with Bonferroni posttests: *** p < 0.001. 
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Figure 31 (continued): Pharmacological acid sphingomyelinase-inhibition ameliorates arthritis severity 
- (B-D) On day 2 after arthritis induction, knee joints were dissected and analyzed by ELISA for the levels of 
IL-1ß (B), IL-6 (C) and IL-17 (D). Data are presented as the amount of the respective cytokine per mg protein 
± SEM of n = 8-11 mice. Asterisks indicate significant differences as assessed by 2-way ANOVA with 
Bonferroni posttests: *** p < 0.001. 
 
Pharmacological inhibition of Asm resulted in a similar reduction of arthritis severity to genetic 
ablation of Asm, as seen both by a reduction of joint swelling (Fig. 31A) and reduced levels of 
pro-inflammatory cytokines in the joint (Fig. 31B-D).  
 
4.2.6 Further studies on platelet-Asm mediated cell adhesion 
As mentioned previously, my colleagues and I first identified the role of platelet-derived Asm 
in melanoma cell metastasis.  In the melanoma model, we have analyzed the mechanism further. 
Through experiments with P-Selectin-deficient mice and in vitro experiments with P-selectin 
glycoprotein ligand, we could show that tumor cells interact with platelets via P- 
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Selectin (Becker et al. 2017). This interaction results in phosphorylation and activation of p38 
MAPK in platelets, followed by secretion of Asm (Carpinteiro et al. 2016; Becker et al. 2017). 
Either genetic deficiency of P-Selectin or pharmacological inhibition of p38 MAPK thus 
resulted in a similar reduction of hematogenous metastasis as Asm-deficiency (Carpinteiro et 
al. 2016; Becker et al. 2017) and metastasis could be restored in P-Selectin-deficient mice by 
pre-incubation of the tumor cells with recombinant ASM (Becker et al. 2017). As these results 
are already published and were obtained in cooperation with my colleagues, they are not 
included in more detail in this thesis.  
The identified platelet-Asm mediated cell adhesion mechanism could also play a role in other 
diseases. Sickle-cell disease, for instance, is a hereditary disorder caused by mutations in the 
beta globin gene (Ingram 1957). Polymerization of mutated hemoglobin leads to red blood cell 
remodeling, triggering vaso-occlusive crises prompted by adhesion of blood cells to the 
vascular wall (reviewed in (Conran, Franco-Penteado, and Costa 2009)). P-selectin has been 
implicated in this process (Ataga et al. 2017) and ASM has been suggested to be involved as 
well (Awojoodu et al. 2014). Therefore, we want to investigate the role of ASM in Sickle-cell 
disease further in the future. To gain a preliminary insight into the relevance of ASM, serum 
was collected from Sickle-cell disease patients and healthy volunteers and the levels of ASM 
activity were compared.  
 
Figure 32: Serum acid sphingomyelinase activity in Sickle-cell disease –  Blood was drawn and serum 
collected from Sickle-cell disease patients and age-matched healthy volunteers. Acid sphingomyelinase (ASM) 
activity in the serum was quantified using BODIPY-sphingoymelin as a substrate. The graph shows reach 
replicate ± SD. Data passed the D’Agostino & Pearson omnibus normality test. The indicated p-value is the 
result of unpaired, two-tailed Student’s t-test.  
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Serum ASM activity was significantly higher in Sickle-cell disease patients than in healthy 
controls. Controls were age-matched to the Sickle-cell disease patients to avoid any potential 
age-dependent differences.  
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5. Discussion 
5.1 Asm inhibition for the treatment of FD  
5.1.1 Phenotypic characterization of the Asah1 knock-out mouse 
FD is a severe, genetic disorder with no cure so far. Little is known about the underlying 
pathologies, except that ceramide accumulates due to mutations in the ASAH1 gene. To 
enable further insights into the disease and, in particular, to facilitate research into new 
therapies, a constitutional Asah1 knock-out model was generated by deletion of Exon1, 
which encodes the signal peptide (Fig. 8A). Two single base pair mutations (Gln22His 
and His23Asp) in the signal peptide sequence have been previously described in FD 
patients (Zhang et al. 2000). This was shown to abrogate lysosomal targeting of Ac (Fig. 
9). Ac has been suggested to undergo autocatalytic cleavage at acidic pH and that this 
maturation step is required for later activity (Shtraizent et al. 2008). Concurrently, 
reduced Ac activities were detected in all tested organs, with a significant reduction in 
the lymphoid organs and the liver (Fig. 10) and an accompanying accumulation of 
ceramide (Fig. 11A).  
Next to the biochemical similarities between FD and our Asah1 knock-out model, the Ac-
deficient mouse line also matched the clinical phenotype of FD patients: Survival was 
shortened (Fig. 12B), the characteristic histiocytic infiltrates were found in several tissues 
(Fig. 13-16), MCP-1 levels – the putative driver of macrophage infiltration (Dworski et 
al. 2017) – were elevated (Fig13D-E) and synovial hyperplasia without other signs of 
inflammatory arthritis was observed in the joints (Fig. 14). Additionally, lung- and liver 
involvement – typically present in the more severe human cases – were also detected (Fig. 
15-17).   
The Asah1 knock-out model thus closely mirrors the human disease. It also matches the 
only other mammalian model of FD – a mouse line with a point-mutation in the Asah1 
gene (Alayoubi et al. 2013). Another previously reported knock-out-model resulted in 
early embryonic lethality already at the four-cell stage (Eliyahu et al. 2007). In contrast 
to the model reported here, this model targeted the catalytic domain of Ac and thus 
abolished Ac activity completely. Through the deletion of Exon1, only lysosomal 
targeting of Ac is blocked (Fig. 9) and residual enzyme activity (Fig. 10) is apparently 
sufficient during embryogenesis. Residual ceramide turnover has also been reported for 
FD patients (Levade, Tempesta, and Salvayre 1993). The residual enzyme activity 
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measured with the NBD-ceramide assay may be the result of ceramide deacetylation by 
other enzymes: Neutral- and alkaline ceramidases 1-3 may have low activity at acidic pH. 
Recently, adiponectin receptors have also been suggested to have ceramidase activity 
(Vasiliauskaite-Brooks et al. 2017). The most likely candidate, given the acidic pH of the 
assay, is N-Acylethanolamine acid amidase, which has been reported to exhibit 
ceramidase-like activity and high sequence similarity to AC (Tsuboi et al. 2005).  
Next to research into FD, the Asah1 knock-out model also enables studies into other 
diseases which have been associated with increased ceramide. For instance, a similar lung 
inflammation as in the Asah1-/- mice has been previously reported in cystic fibrosis mice 
that also accumulate pulmonary ceramide (Teichgräber et al. 2008). The hepatic 
pathologies, such as the elevations of liver transaminases and LDH reported here, have 
already been linked to ceramide accumulation and even led to noninvasive hepatocellular 
carcinoma in a ceramide synthase 2 knock-out model (Pewzner-Jung et al. 2010). Thus, 
the Asah1 knock-out model is also very relevant outside the context of FD and the 
assessment of Asm inhibition to target pathological ceramide accumulation potentially 
also has broader clinical implications (please refer to table 2 for a list of ASM/ceramide-
mediated diseases).  
 
5.1.2 New insights into the pathophysiology of Farber Disease  
Next to assessing the known indicators of FD in the Asah1 knock-out model, other parameters 
were also assessed to garner further insights into the pathophysiology of FD and ceramide 
accumulation.  
Next to ceramide, total sphingomyelin and C16-sphignomyelin also accumulated, although not 
significantly. Nevertheless, this 3-5 fold increase is a new finding, since sphingomyelin levels 
have not yet been investigated in detail in FD. So far, only one report has suggested an increase 
in d18:2 and 24:1 sphingomyelin (Jones et al. 2014). Increased sphingomyelin levels may 
contribute to FD manifestations: Niemann-Pick disease type A+B are caused by sphingomyelin 
accumulation due to ASM deficiency and share some features with FD, including foam cell 
infiltration and pulmonary, hepatic and central nervous system involvement (reviewed in 
(Schuchman and Desnick 2017)). 
Hematological manifestations of FD have been suggested in some case reports (Antonarakis et 
al. 1984; Fujiwaki et al. 1992; Mondal et al. 2009), but where not reported with any clear 
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consistency. Differential blood counts of Ac-deficient mice showed a reduction in white blood 
cells, a trend toward reduced platelet numbers and increased red blood cell number with reduced 
mean corpuscular hemoglobin concentration (Fig. 18). The reduction of white blood cells both 
matches and contrasts reports from the Asah1 point mutation model: Initially, significant 
elevations of peripheral blood leukocytes were reported (Alayoubi et al. 2013), but a later study 
detailed perturbed hematopoiesis in Ac-deficient mice due to damage to the stem cell niche by 
foam cells (Dworski et al. 2015). The changes to the red blood cell count and erythrocyte indices 
observed in our model require further studies. Despite the normal hemoglobin levels, these 
changes may reflect an imbalance of cellular iron distribution as the result of chronic disease. 
The observed elevation of CPK levels (Fig. 19) fits well with reports of CPK elevation in spinal 
muscular atrophy patients (Rudnik-Schoneborn et al. 1998) as mutations in the ASAH1 gene 
have not only been reported in FD, but also in spinal muscular atrophy (Dyment et al. 2014; 
Filosto et al. 2016; Gan et al. 2015; Zhou et al. 2012) and a subset of patients suffer from both 
FD and spinal muscular atrophy (Teoh et al. 2016). Ac-deficient mice also showed some 
indicators of muscular dystrophy (progressive waisting, scoliosis, waddling gate). The data 
indicates that determination of CPK levels in FD patients may be a useful biomarker for the 
disease in order to help to distinguish FD from juvenile idiopathic arthritis, for which FD is 
commonly misdiagnosed (Sólyom et al. 2014; Torcoletti et al. 2014).  
The failure of Ac-deficient mice to thrive and their progressive waisting (Fig. 11A) match 
reports that FD patients also have poor weight gain (Moser 2001). To gain further insight, a 
metabolic analysis was conducted. Serum glucose levels were significantly decreased in  
Asah1-/- mice and seemed to decline progressively (Fig. 20A). Insulin levels could not be 
reported, because they remained below the detection limit of the assay. Thus, while an over-
production of Insulin cannot be excluded as the cause of the observed hypoglycemia in FD 
mice, it seems unlikely. As decreased glucose levels might also be the result of reduced food 
intake and starvation, levels of the ketone body ß-hydroxybutyrate were analyzed in the urine. 
Ketonuria occurs when the body uses fat as an energy source rather than carbohydrates, e.g. 
during starvation or in type I diabetes mellitus. Ac-deficient mice, however, showed no signs 
of ketonuria (Fig. 20B), arguing against that.  
Interestingly, we found that Ac-deficient mice loose significantly more glucose in the urine than 
their Wt littermates (Fig. 21D). This did not appear to be the result of a general filtration  
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defect, since Asah1-/- mice showed no histopathological signs of renal disease (Fig. 21A) and 
urinary protein excretion was reduced rather than elevated (Fig. 21C).  
A plausible scenario for the reduction of blood glucose in combination with the loss of glucose 
through the urine in the absence of a general filtration defect would be a specific impairment of 
intestinal glucose uptake and renal glucose reabsorption. Both are mediated by sodium-glucose 
linked transporters (SGLT). These are secondary active transporters, meaning that they are 
dependent on the sodium-potassium adenosine triphosphatase (Na+/K+-ATPase) driven sodium 
gradient. Increased ceramide levels could interfere either with the function of SGLT proteins 
or with the function of Na+/K+-ATPase through alteration of their lipid environment, in a similar 
mechanism to the previously reported ceramide-mediated inhibition of the potassium channel 
Kv1.3 (Bock et al. 2003). This would inhibit glucose uptake and reabsorption. Alternatively, or 
in combination to this, ceramide might also downregulate the expression of nutrient 
transporters, as has been suggested by a previous in vitro study (Guenther et al. 2008).  
We plan to investigate the role of ceramide in glucose uptake and reabsorption further in the 
future. If ceramide accumulation indeed impairs glucose uptake, patients might benefit from a 
diet with a high content of membrane-permeant energy sources, e.g. methyl pyruvate, by 
improving their general constitution and resistance.  
Given that indicators of kidney function were altered upon Ac-deficiency (Fig. 21A), however, 
further studies into the effects of ceramide accumulation in the kidneys are also necessary. For 
instance, it is currently unclear whether BUN levels are increased due to renal dysfunction or 
as the result of the reported liver disease (Fig. 16-17).   
 
5.1.3 Effects of Asm-inhibition on Farber Disease manifestations  
Having established the usefulness of the Asah1 knock-out mouse line as a model of FD, a rescue 
study was conducted to assess the suitability of Asm depletion as a new treatment strategy for 
FD. For this, the Ac-deficient line was cross-bred to an Asm-deficient mouse line. Genetic 
ablation of Asm significantly blunted ceramide accumulation in Ac-deficient mice (Fig. 11), 
resulting in improved weight gain and survival (Fig. 12). Histiocytic infiltrations were also 
significantly reduced or completely absent in the double-deficient mice in all organs except for 
the lung and liver (Fig. 13-16). Liver fibrosis, however, was successfully reduced by Asm-
deficiency (Fig. 16). Clinical chemistry analysis also showed marked improvements  
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in liver parameters (Fig. 17), blood count (Fig. 18), CPK levels (Fig. 19), serum glucose (Fig. 
20A) and kidney indices (Fig. 21). Heterozygous depletion had only limited success: Most 
parameters improved somewhat, e.g. particularly liver transaminases (Fig. 17) and CPK levels 
(Fig. 19), but the median survival time could only be improved by a few days (Fig. 12B).  
Despite the significantly enhanced survival time of Ac- and Asm-double deficient mice and the 
beneficial effect on most FD manifestations, pharmacological inhibition of Asm was 
unsuccessful: Juvenile Ac-deficient mice died within a few days of Amitriptyline treatment, 
thus even significantly shortening the survival time of Ac-deficient mice (Fig. 22). Treatment 
with Amitritpyline throughout development had similar outcomes (Fig. 23). Amitriptyline 
seems to have a toxic effect specifically in Ac-deficient mice, as vehicle treatment or treatment 
of wild-type littermates had no adverse effects (Fig. 22-23). Potentially, this toxicity arises from 
suppression of residual Ac activity in Ac-deficient mice: Amitriptyline functionally inhibits 
Asm by interfering with Asm-membrane binding (Kornhuber et al. 2008). Ac also has to attach 
to the inner lysosomal membrane and even exists in a complex with Asm  (He et al. 2003). It 
could thus be displaced from the lysosomal membrane by Amitriptyline in the same fashion as 
Asm. Another tricyclic antidepressant and functional inhibitor of ASM – Desipramine – has 
already been reported to co-inhibit AC in this manner (Elojeimy et al. 2006). Given that 
lysosomal targeting of Ac is disrupted Ac-deficient mice, however, the open question is how 
such a co-inhibition would be possible. Putatively, small amounts of the mislocated enzyme 
could be secreted and taken up by endocytosis, thus being delivered to the lysosomes. Cell 
culture experiments with conditioned medium support such a cross-correction effect (data not 
shown), as well as the residual Ac activity detected in organs of Ac-deficient mice (Fig.  10) 
and the reported successes of allogenic stem cell transplantation on FD manifestations (Ehlert 
et al. 2006; Torcoletti et al. 2014). A cross-correction effect would also help to explain why our 
knock-out model is not embryonic lethal, whereas a previously reported model lacking the 
catalytic domain could not survive past the four-cell stage (Eliyahu et al. 2007). 
 
Another possible explanation is that the existing damage from FD manifestations, particularly 
in the liver (Fig. 16-17) and putatively also in the heart (Fig. 19), sensitize Ac-deficient mice to 
the toxic side effects of Amitriptyline. Adverse effects of Amitriptyline are known to include 
liver injury (Voican et al. 2014) and cardiotoxicity (Sari et al. 2011). Thus, Ac-deficient mice 
may be more susceptible to Amitriptyline poisoning.  
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Alternatively, altering sphingolipid metabolism after immense amounts of ceramide have 
already accumulated might trigger a toxic surge of redistribution to other sphingolipids. This 
was the rationale for treating one group with Amitriptyline throughout development, since this 
should have prevented ceramide accumulation in the first place. As Amitriptyline has been 
reported to cross the placenta (Heikkinen, Ekblad, and Laine 2001) and to be present in breast 
milk (Yoshida et al. 1997) upon treatment of the mothers, such an approach should have been 
feasible. As FD diagnosis is possible prenatally (Fensom et al. 1979), such a treatment regimen 
could at least potentially also be translated clinically. However, treatment throughout 
development had a similar effect to the treatment of juvenile Ac-deficient mice: Both groups 
died around the time that they were weaned/received Amitriptyline directly. Therefore, the 
extent of Asm inhibition was assessed in the group treated throughout development, but no 
reduction in Asm activity could be observed, although adult animals treated with the same dose 
showed an approximately 80 % reduction. In conclusion, Amitriptyline treatment could 
potentially be beneficial for the treatment of Farber Disease, if it was supplied in sufficient 
doses and before too much ceramide has accumulated. However, the results obtained in this 
study strongly caution against the use of any tricyclic antidepressants and other functional 
inhibitors of ASM in FD patients, given the previously undescribed toxicity of these compounds 
upon Ac-deficiency.  
 
5.2 Asm inhibition for the treatment of RA  
RA is a chronic autoinflammatory disorder with a high socioeconomic impact. Despite several 
symptomatic treatments, RA often progresses to disability and new treatment strategies are in 
high demand. This study newly identifies Asm as a key player in joint inflammation and 
introduces ASM as a new druggable target in RA. The role of Asm in joint inflammation was 
assessed with the murine antigen-induced arthritis model. Asm-deficient mice showed reduced 
arthritis severity (Fig. 25-26). A possible mechanism that explains the protection of Asm-
deficient mice against arthritis could be lack of platelet activation and release of Asm from 
platelets upon contact with lymphocytes, preventing clustering of ß1-Integrin on lymphocytes 
and thereby extravasation. This potential mechanism is graphically summarized below.   
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Figure 33: Proposed mechanism for regulation of arthritis severity by acid sphingomyelinase -  An 
initiating event damages the joint (1). As a result, the endothelium is activated and recruits platelets (2). These 
then interact with circulating lymphocytes via release of Asm (3). Through the subsequent formation of 
ceramide-enriched platforms on the lymphocytes, ß1-Integrin is activated (4), enabling lymphocyte-adhesion 
to the activated endothelium and infiltration into the damaged joint (5).   
 
The first steps of the proposed model (endothelial activation and platelet accumulation upon 
joint damage) have been reported previously (Schmitt-Sody, Metz, Klose, et al. 2007; Schmitt-
Sody, Metz, Gottschalk, et al. 2007). The following steps – Asm release by platelets and 
subsequent cell extravasation – are new in the context of lymphocytes, but appear to be 
essentially identical to the mechanism my colleagues and I have previously described for 
melanoma metastasis (Becker et al. 2017; Carpinteiro et al. 2015; Carpinteiro et al. 2016). 
Unfortunately, it was not possible to investigate the activation status of ß1-Integrin on murine 
lymphocytes directly in the antigen-induced arthritis model, since no activation-specific 
antibody against murine ß1-Integrin is available. Instead, ß1-Integrin activation was analyzed 
in human PBMCs with the activation-specific anti-human ß1-Integrin antibody (clone HUTS-
4). With the help of this antibody, sphingomyelinase-stimulation was shown to activate ß1-
Integrin on lymphocytes (Fig. 30). Previous report show that sphingomyelinase-stimulation 
results in the formation of ceramide-enriched plasma membrane platforms and that these cluster 
ß1-Integrin molecules – a pre-requisite for integrin activation (Carpinteiro et al. 2015). The 
mechanistic details of ß1-Integrin activation upon sphingomyelinase-stimulation still require 
further definition: It is currently unclear whether ceramide only mediates the clustering of ß1-
Integrin molecules and their activation is achieved through distinct signaling  
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pathways, or whether the interaction with ceramide modifies the conformation of ß1-Integrin 
directly and thereby results in activation.  
Another possible explanation of the findings reported here would be any defect in Asm-
deficient lymphocytes or lymphocyte stimulation that result in ß1-Integrin activation and/or 
prevents adhesion and/or emigration of lymphocytes in vivo. These upstream steps could 
potentially be bypassed by transfusion of pre-activated wild-type platelets into Asm-deficient 
mice, allowing the development of arthritis in Asm-deficient mice non-specifically. Further, 
arthritis could not be restored completely to Asm-deficient mice upon transfusion of Wt 
platelets (Fig. 29), which might indicate additional functions of Asm, for instance for 
emigration into the tissue. It may also reflect a technical problem due to incomplete 
reconstitution of platelet functions, because approximately 55 % of host platelets remain after 
transfusion (Carpinteiro et al. 2015). Thus, slightly more than half of all present platelets are 
still Asm-deficient and cannot release Asm to recruit lymphocytes to the joints. 
It is also possible, however, that further endothelial and/or synovial Asm-effects are at play, 
which are not reconstituted upon Wt-platelet transfusion. A functional defect in Asm-deficient 
lymphocytes as the cause, however, seems improbable due to the results obtained here, as both 
proliferative and functional responses to the immunization antigen were unaffected by Smpd1 
knock-out (Fig. 28) and T- and B-cell populations did not differ between Wt- and Smpd1-/- mice 
in response to immunization (Fig. 27). The frequency of regulatory T cells was also not altered, 
which seems to contrast a previous study by Hollmann et al., which reported an increase of 
regulatory T cells in Smpd1-/- mice (Hollmann et al. 2016). Whereas the Hollmann-study 
analyzed untreated mice, this study considered only immunized mice, thus indicating that the 
immunization is a stimulus strong enough to overcome these baseline differences.  
The data presented here also apparently contrast another study that reported a role of ASM in 
modulating T-helper cell responses (Bai et al. 2015). However, only FIASMAs were employed 
in this study, which can have diverse additional off-target effects (Glowinski and Axelrod 1964; 
Jang et al. 2009; Owens et al. 1997), including effects on different ion channels (Arita et al. 
1987; Pancrazio et al. 1998; Park et al. 1998; Punke and Friederich 2007; Schofield et al. 1981; 
Wooltorton and Mathie 1995) and the induction and degradation of other lysosomal enzymes 
(Elojeimy et al. 2006). Importantly, exogeneous ceramide failed to rescue T-helper cells from 
ASM-inhibition in the Bai-study, arguing against a specific Asm-dependent effect in the 
regulation of T-helper cell responses (Bai et al. 2015). 
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Regarding platelets, reports concerning the role of Asm in platelet-degranulation vary. In their 
previous metastasis-experiments, my colleagues have observed no impairments in platelet-
aggregometrical properties upon Asm-deficiency (Carpinteiro et al. 2015). One study, however, 
notes some changes in platelet function upon Asm-deficiency, including blunted ATP release, 
P-Selectin- and phosphatidylserine exposure and thrombin generation (Munzer et al. 2014). 
Functional properties like platelet αIIß3 activation and aggregation, activation-dependent Ca2+-
flux and bleeding time were not affected (Munzer et al. 2014). Therefore, it cannot be 
completely excluded that activation-dependent platelet functions are perturbed by Smpd1 
knock-out. Even if Asm-deficiency would cause a defect in classical platelet function, however, 
it is unclear how relevant this would be in this context, given that inhibitors of classical platelet 
functions do not ameliorate arthritis severity (Boilard et al. 2011; Boilard et al. 2010; Forrest et 
al. 2006; Garcia et al. 2011). Platelet-depletion, on the other hand, does (Boilard et al. 2010). 
Thus, it appears that platelet-activation in RA involves a mechanism that is distinct from the 
typical thrombosis pathway. The suppression of arthritis severity upon Asm-deficiency and 
Amitriptyline-treatment and the lack of arthritis reconstitution upon transfusion of Asm-
deficient platelets to Asm-deficient mice reported in this study, suggests that release of Asm by 
platelets is this new mechanism. However, further studies are necessary to strengthen this 
hypothesis, i.e. a demonstration of Asm secretion by platelets, clustering and activation of ß1-
Integrin on lymphocytes and enhanced adhesion of lymphocytes upon platelet and lymphocyte 
co-incubation. These studies will also help to distinguish whether the suggested hypothesis 
concerning Asm secretion by platelets is indeed the determinant of arthritis severity, or if 
arthritis severity is instead ameliorated by a defect in Asm-deficient lymphocyte or lymphocyte 
stimulation in Asm-deficient mice that results in ß1-Integrin activation and/or prevents 
adhesion and/or emigration of lymphocytes in vivo.  
Given the findings of the present studies, ASM inhibition is an attractive new target for the 
treatment of RA in humans. FIASMAs have been clinically used for decades and are quite save 
and well suited for long-term therapy – a definite benefit compared to GCs, for instance, which 
should only be administered for the shortest possible time due to the potentially severe adverse 
effects (Saag 1997; van der Goes et al. 2010). The toxicity and tolerability of the current gold 
standard of care – MTX – also leaves a lot to be desired, given that the incidence rate of severe 
adverse events is up to 3-5 % and given its additional abortifacient and teratogenic properties 
(Zitnik and Cooper 1990). While new biological agents for the treatment of RA are making 
progress on their way into the clinic, these new treatments – if they are successful - will be quite 
expensive and their administration may also require i.v.  
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injections (e.g. Rituximab). Thus, Amitriptyline or other FIASMAs do not only have the 
advantage of being well tolerated, but are also easy to administer and inexpensive.  
ASM inhibition may not only benefit RA patients, but also patients suffering from other chronic 
(auto-)inflammatory diseases, as the putative mechanism reported here is not joint-specific, but 
rather affects lymphocyte recruitment in general. Thus, future applications of FIASMAs could 
potentially also include diseases such as multiple sclerosis, psoriasis or inflammatory bowel 
disease. Moreover, the preliminary data on Sickle cell disease (Fig. 32) indicates that even some 
non-inflammatory diseases involving cell adhesion might be new targets for ASM inhibition.  
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